Document:

-- Converted by SEC Publisher, created by BCL Technologies Inc., for SEC Filing

Exhibit 10.2

SAVIENT PHARMACEUTICALS, INC. 

WARRANT TO PURCHASE
COMMON STOCK 

  Warrant No.: [___]

  Number of Shares of Common Stock: [_____________]

 Date of Issuance: April 8, 2009 (“Issuance Date”) 

       Savient Pharmaceuticals,
  Inc., a Delaware corporation (the “Company”), hereby certifies
  that, for good and valuable consideration, the receipt and sufficiency of which
  are hereby acknowledged, [______________], the registered holder hereof or
  its permitted assigns (the “Holder”), is entitled, subject
  to the terms set forth below, to purchase from the Company, at the Exercise
  Price (as defined below) in effect at the time of exercise, upon surrender
  of this Warrant to Purchase Common Stock (including any Warrants to Purchase
  Common Stock issued in exchange, transfer or replacement hereof, the “Warrant"),
  at any time or times on or after the date hereof, but not after 11:59 p.m.,
  New York time, on the Expiration Date (as defined below), [______________ (_____________)]1 fully
  paid nonassessable shares of Common Stock (as defined below) (the
“Warrant Shares”). Except as otherwise defined herein, capitalized
terms in this Warrant shall have the meanings set forth in Section 15.
As used herein, the “Exercise Period” means the period beginning
on the date hereof and ending at 11:59 p.m., New York time, on the Expiration
Date. This Warrant is the Warrant to purchase Common Stock issued pursuant to Section
2 of
that certain Subscription Agreement (the “Subscription Agreement”),
dated as of April 2, 2009 (the “Subscription Date”), by and
between the Company and the Holder (the “Subscription Agreement”),
and is issued pursuant to the Company’s
Registration Statement on Form S-3 (File number 333-146257) (the “Registration
Statement”). 

       1. EXERCISE OF WARRANT. 

            (a) Mechanics
  of Exercise. Subject to the terms and conditions
  hereof, this Warrant may be exercised by the  Holder on any day during the
  Exercise Period, in whole or in part, by (i) delivery of a written notice,
  in the form attached hereto as Exhibit A (the “Exercise
Notice”), of the Holder's election to exercise this Warrant and (ii)
(A) payment to the Company of an amount equal to the Exercise Price in effect
at the time of exercise multiplied by the number of Warrant Shares as to which
this Warrant is being exercised (the “Aggregate Exercise Price”)
in cash or by wire transfer of immediately available funds or (B) by notifying
the Company that this Warrant is being exercised pursuant to a Cashless Exercise
(as defined in Section 1(e)); provided, however,
that, notwithstanding Section 1(a)(ii)(A), at any time, upon receipt of an Exercise
Notice, the Company may, in its sole discretion, require that the Holder exercise
this Warrant on a Cashless  Exercise basis (in which case, if the Holder has
exercised the Warrant by payment of the Aggregate Exercise Price pursuant to
Section 1(a)(ii)(A), the Company shall promptly return such funds to an account
designated by the Holder, and the Holder  shall, for all purposes hereunder,
be deemed to have delivered a notice of Cashless 

_________________________

1 Insert a number of shares equal to 85% of the number of shares of Common Stock purchased under the Subscription Agreement. 

  Exercise with respect to such exercise on the date on which the Exercise Notice was delivered, or alternatively, at the election of the Holder, the Exercise Notice shall be null and void).  The Holder shall not be required to
deliver the original Warrant in order to effect an exercise hereunder, but shall deliver the original Warrant within five (5) Business Days thereafter. Execution and delivery of the Exercise Notice with respect to less than all of the Warrant Shares
shall have the same effect as cancellation of the original Warrant and issuance of a new Warrant evidencing the right to purchase the remaining number of Warrant Shares. On or before the first (1st) Business Day following the date on which the Company has received,
as applicable, each of the Exercise Notice and the Aggregate Exercise Price (or
notice of a Cashless Exercise) (the “Exercise Delivery
Documents”), the Company shall transmit by facsimile an acknowledgment of
confirmation of receipt of the Exercise Delivery Documents to the Holder and
the Company's transfer agent (the “Transfer Agent”). On or before the
third (3rd) Business Day following the date on which the Company has
received all of the Exercise Delivery Documents (the “Share Delivery Date”),
the Company shall (X) provided that the Transfer Agent is participating in The
Depository Trust Company (“DTC”) Fast Automated Securities Transfer Program,
upon the request of the Holder, credit such aggregate number of Warrant Shares
to which the Holder is entitled pursuant to such exercise to the Holder's or
its designee's balance account with DTC through its Deposit Withdrawal Agent
Commission system, or (Y) if the Transfer Agent is not participating in the DTC
Fast Automated Securities Transfer Program, issue and dispatch by overnight courier
to the address as specified in the Exercise Notice, a certificate, registered
in the Company's share register in the name of the Holder or its designee, for
the number of shares of Common Stock to which the Holder is entitled pursuant
to such exercise. Upon delivery of the Exercise Delivery Documents, the Holder
shall be deemed for all corporate purposes to have become the holder of record
of the Warrant Shares with respect to which this Warrant has been exercised,
irrespective of the date such Warrant Shares are credited to the Holder's DTC
account or the date of delivery of the certificates evidencing such Warrant Shares,
as the case may be. If this Warrant is submitted in connection with any exercise
pursuant to this Section 1(a) and the number of Warrant Shares represented by
this Warrant submitted for exercise is greater than the number of Warrant Shares
being acquired upon an exercise, then the Company shall as soon as practicable
and in no event later than two Business Days after receipt by the Company, following
an exercise of the Warrant, of the original Warrant, and at its own expense,
issue a new Warrant (in accordance with Section 8(d)) representing the
right to purchase the number of Warrant Shares purchasable under this Warrant after giving effect to such exercise of the Warrant. No fractional shares of Common Stock are to be issued upon the exercise of this Warrant, but rather the number of
shares of Common Stock to be issued shall be rounded up to the nearest whole number. The Company shall pay any and all transfer taxes which may be payable with respect to the issuance and delivery of Warrant Shares upon exercise of this Warrant by
the Holder of this Warrant.

            (b) Exercise Price.
  For purposes of this Warrant,“Exercise
Price” initially means $10.46, subject to adjustment as provided herein.
In the event that, during the Exercise Period, the Company publicly announces
that the United States Food and Drug Administration (“FDA”) has issued a “complete response” letter
(the “Complete Response Letter”) with respect to the
Company’s Biologics License Application for the Company’s KRYSTEXXA
product candidate (the “BLA”), as set forth in a writing by the FDA under 21 C.F.R. § 601.3
(the date of such announcement, the “Complete Response Date”),
then the Exercise Price shall, from and after the eleventh Trading Day following
the Complete Response

  Date, be changed to be the Market Price, subject to adjustment as provided herein; provided, however,
  that in no event shall the Exercise Price (i) exceed $10.46 or (ii) be less than $1.57,
  in each case subject to appropriate adjustment in the event of any stock dividend,
  stock split, combination or other similar recapitalization with respect to
the Common Stock. 

            (c) Market Price.
  For purposes of this Warrant, “Market
Price” means the Weighted Average Price for the Common Stock for the
five (5) Trading Days immediately preceding the tenth Trading Day following the
Complete Response Date. 

            (d) Company's Failure to Timely Deliver Securities.  If the Company shall fail for any reason or for no reason
to issue to the Holder within three (3) Business Days of receipt of the Exercise Delivery Documents in compliance with the terms of this Section 1, a certificate for the number of shares of
Common Stock to which the Holder is entitled and register such shares of Common Stock on the Company's share register or to credit the Holder's balance account with DTC for such number of shares of Common Stock to which the Holder is entitled upon
the Holder's exercise of this Warrant, and if on or after such Trading Day the Holder purchases (in an open market transaction or otherwise) shares of Common Stock to deliver in satisfaction of a sale by the Holder of shares of Common Stock issuable
upon such exercise that the Holder anticipated receiving from the Company (a “Buy-In”), then the Company shall, within three (3) Business Days after the Holder's request and in the Holder's
discretion, either (i) pay cash to the Holder in an amount equal to the Holder's total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased (the “Buy-In
Price”), at which point the Company's obligation to deliver such certificate
(and to issue such Warrant Shares) shall terminate (and, if the Company’s transfer agent delivers such Warrant Shares thereafter, the
Holder will promptly work with the transfer agent, at the Company’s expense,
to return such Warrant Shares), or (ii) promptly honor its obligation to deliver
to the Holder a certificate or certificates representing such Warrant Shares
and pay cash to the Holder in an amount equal to the excess (if any) of the Buy-In
Price over the product of (A) such number of shares of Common Stock, times (B)
the Closing Sale Price on the date of exercise. 

            (e) Cashless
  Exercise.  Upon the
  election of a  Holder pursuant to Section 1(a)(ii)(B) or an election
  by the Company to require that this Warrant be exercised on a Cashless Exercise
  basis pursuant to the proviso in the first sentence of
Section 1(a), this Warrant shall be exercised by the Holder hereof, in
whole or in part and, in lieu of making a cash payment otherwise contemplated
to be made to the Company upon such exercise in payment of the Aggregate Exercise
Price, by the Holder’s receiving upon such exercise the “Net Number" of
shares of Common Stock determined according to the following formula (a “Cashless
 Exercise”): 

  Net Number = (A x B) - (A x C) 

                                   B

  For purposes of the foregoing formula:

  A= the total number of shares with respect to which this Warrant is then being exercised. 

  B= the arithmetic average of the Closing Sale Prices of the shares of Common Stock for the five (5) consecutive Trading Days ending on the date immediately preceding the date of the Exercise Notice; provided, however, that if
  the Company requires that this Warrant be exercised on a Cashless Exercise
  basis pursuant to the proviso in the first sentence of Section 1(a), “B” shall
  instead equal the greater of (i) the arithmetic average of the Closing Sale
  Prices of the shares of Common Stock for the five (5) consecutive Trading Days
  ending on the date immediately preceding the date of the Exercise Notice and
(ii) the Closing Sale Price on the date of the Exercise Notice. 

  C= the Exercise Price then in effect for the applicable Warrant Shares at the time of such exercise. 

            (f) Rule 144.  For purposes of Rule 144(d) promulgated under the Securities Act, as in effect on the date
hereof, assuming the Holder is not an affiliate of the Company, it is intended that the Warrant Shares issued in a Cashless Exercise shall be deemed to have been acquired by the Holder, and the holding period for the Warrant Shares shall be deemed
to have commenced, on the date this Warrant was originally issued pursuant to the Subscription Agreement 

            (g) Disputes.  In the case of a dispute as to the determination of the Exercise Price or the arithmetic
calculation of the Warrant Shares, the Company shall promptly issue to the Holder the number of Warrant Shares, if any, that are not disputed. 

            (h)  Beneficial Ownership.
  The Holder shall not have the right to exercise this Warrant to the extent
  that after giving effect to such exercise, the Holder (together with the Holder’s
  affiliates) would beneficially own in excess of [4.99/9.99%] (the “Maximum Percentage”)
  of the shares of Common Stock outstanding immediately after giving effect to
  such exercise. If the Holder has delivered an Exercise Notice, the Company
  shall be entitled to assume that such exercise will not result in the Holder
  exceeding the Maximum Percentage as a result of the exercise contemplated by
  such Exercise Notice. For purposes of the foregoing sentence, the aggregate
  number of shares of Common Stock beneficially owned by such Holder and its
  affiliates shall include the number of shares of Common Stock issuable upon
  exercise of this Warrant with respect to which the determination of such sentence
  is being made, but shall exclude shares of Common Stock which would be issuable
  upon (i) exercise of the remaining, unexercised portion of this Warrant beneficially
  owned by such Person and its affiliates and (ii) exercise or conversion of
  the unexercised or unconverted portion of any other securities of the Company
  beneficially owned by such Person and its affiliates (including, without limitation,
  any convertible notes or convertible preferred stock or warrants) subject to
  a limitation on conversion or exercise analogous to the limitation contained
  herein. Except as set forth in the immediately preceding sentence, for purposes
  of this paragraph, beneficial ownership shall be calculated in accordance with
  Section 13(d) of the Securities Exchange Act of 1934, as amended. For purposes
  of this Warrant, in determining the number of outstanding shares of Common
  Stock, the Holder may rely on the number of outstanding shares of Common Stock
  as reflected in the most recent of (1) the Company's most recent Form 10-K,
Form 10-Q, Current Report on Form

  8-K or other public filing with the Securities and Exchange Commission, as the case may be, (2) a public announcement by the Company or (3) any other notice by the Company or the Transfer Agent setting forth the number of shares
of Common Stock outstanding. For any reason at any time, upon the written or oral request of the Holder, the Company shall within two (2) Business Days confirm orally and in writing to the Holder the number of shares of Common Stock then
outstanding.  In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder and its affiliates since the date
as of which such number of outstanding shares of Common Stock was reported.  By written notice to the Company, the Holder may from time to time increase or decrease the Maximum Percentage to any other percentage specified in such notice and not in
excess of [4.99/9.99%]; provided that any such increase will not be effective until the sixty-first (61st) day after such notice is
delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 1(h) to correct
this paragraph (or any portion hereof) which may be defective or inconsistent with the intended beneficial ownership limitation herein contained or to make changes or supplements necessary or desirable to properly and reasonably give effect to such
limitation. 

       2. ADJUSTMENT OF EXERCISE PRICE AND NUMBER OF WARRANT SHARES. The Exercise Price and the number of Warrant
Shares shall be adjusted from time to time as follows: 

            (a) Adjustment upon Subdivision or Combination of Common Stock. If the Company at any time on or after the
Subscription Date subdivides (by any stock split, stock dividend, recapitalization, reorganization, scheme, arrangement or otherwise) one or more classes of its outstanding shares of Common Stock into a greater number of shares, the Exercise Price
in effect immediately prior to such subdivision will be proportionately reduced and the number of Warrant Shares will be proportionately increased. If the Company at any time on or after the Subscription Date combines (by any stock split, stock
dividend, recapitalization, reorganization, scheme, arrangement or otherwise) one or more classes of its outstanding shares of Common Stock into a smaller number of shares, the Exercise Price in effect immediately prior to such combination will be
proportionately increased and the number of Warrant Shares will be proportionately decreased. Any adjustment under this Section 2(b) shall become effective at the close of business on the date the subdivision or combination becomes effective.  For
the avoidance of doubt, if the Exercise Price is adjusted as a result of the occurrence of the Complete Response Date, then the Exercise Price so adjusted shall be in effect, without regard to any adjustment as a result of any subdivision or
combination of the Common Stock described in this Section 2(a) that may have occurred prior to the date on which the adjustment resulting from the occurrence of the Complete Response Date occurs, but the Exercise Price shall thereafter be adjusted
to reflect any subdivision or combination of the Common Stock described in this Section 2(a) that may occur on or after the date on which the adjustment resulting from the occurrence of the Complete Response Date occurs. 

       3. RIGHTS UPON DISTRIBUTION OF ASSETS.  If the Company shall declare or make any dividend or other
distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by
way of a

  dividend, spin off, reclassification, corporate
  rearrangement, scheme of arrangement or other similar transaction) (a “Distribution”),
at any time after the issuance of this Warrant, then, in each such case: 

            (a) any Exercise Price in effect immediately prior to the close of business on the record date fixed for the determination of holders of shares
of Common Stock entitled to receive the Distribution shall be reduced, effective as of the close of business on such record date, to a price determined by multiplying such Exercise Price by a fraction of which (i) the numerator shall be the Closing
Bid Price of the shares of Common Stock on the Trading Day immediately preceding such record date minus the value of the Distribution (as determined in good faith by the Company's Board of Directors) applicable to one share of Common Stock, and (ii)
the denominator shall be the Closing Bid Price of the shares of Common Stock on the Trading Day immediately preceding such record date; and 

            (b) the number of Warrant Shares shall be increased to a number of shares equal to the number of shares of Common Stock obtainable immediately
prior to the close of business on the record date fixed for the determination of holders of shares of Common Stock entitled to receive the Distribution multiplied by the reciprocal of the fraction set forth in the immediately preceding paragraph
(a); provided that
in the event that the Distribution is of shares of Common Stock (or common stock)
("Other Shares of Common Stock") of a company whose common shares are traded
on a national securities exchange or a national automated quotation system, then
the Holder may elect to receive a warrant to purchase Other Shares of Common
Stock in lieu of an increase in the number of Warrant Shares, the terms of which
shall be identical to those of this Warrant, except that such warrant shall be
exercisable into the number of shares of Other Shares of Common Stock that would
have been payable to the Holder pursuant to the Distribution had the Holder exercised
this Warrant immediately prior to such record date and with an aggregate exercise
price equal to the product of the amount by which the exercise price of this
Warrant was decreased with respect to the Distribution pursuant to the terms
of the immediately preceding paragraph (a) and the number of Warrant Shares calculated
in accordance with the first part of this paragraph (b). 

  For the avoidance of doubt, if the Exercise Price is adjusted as a result of the occurrence of a Distribution, then the Exercise Price so adjusted shall be in effect, without regard to any adjustment as a result of a Distribution
that may have occurred prior to the date on which the adjustment resulting from the occurrence of the Complete Response Date occurs, but the Exercise Price shall thereafter be adjusted to reflect any Distribution that may occur on or after the date
on which the adjustment resulting from the occurrence of the Complete Response Date occurs. 

       4. PURCHASE RIGHTS; FUNDAMENTAL TRANSACTIONS. 

            (a) Purchase Rights.
  In addition to any adjustments pursuant to Section 2 above, if at any time
  the Company grants, issues or sells any Options, Convertible Securities or
  rights to purchase stock, warrants, securities or other property pro rata to
  the record holders of any class of shares of Common Stock (the “Purchase
Rights”) (and not, for the avoidance of doubt, equity awards to employees,
directors or consultants), then the Holder will be entitled to acquire, upon
the terms applicable to such Purchase Rights, the aggregate Purchase Rights which
the Holder could have acquired if the Holder had held the number of shares of
Common Stock 

  acquirable upon complete exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights,
or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights. 

            (b) Fundamental Transactions.
  The Company shall not enter into or be party to a Fundamental Transaction unless
  the Successor Entity assumes this Warrant in accordance with the provisions
  of this Section 4(b) and delivers to each holder of Warrants in exchange for
  such Warrants, promptly following consummation of such Fundamental Transaction,
  a new Warrant substantially similar in form and substance to this Warrant reflecting
  any modification in the terms of the Warrant pursuant to this Section 4(b).
  If, at any time prior to the Expiration Date, the Company enters into or is
  a party to a Fundamental Transaction pursuant to which holders of shares of
  Common Stock are entitled or required to receive securities issued by another
  company or cash or other assets with respect to or in exchange for shares of
  Common Stock (a “Corporate Event”), the Holder shall thereafter
  have the right to receive upon an exercise of this Warrant for each Warrant
  Share that would have been issuable upon exercise of this Warrant prior to
  consummation of such Corporate Event, in lieu of the shares of the Common Stock
  (or other securities, cash, assets or other property) purchasable upon the
  exercise of the Warrant prior to such Corporate Event, such shares of stock,
  securities, cash, assets or any other property whatsoever (including warrants
  or other purchase or subscription rights) which the Holder would have been
  entitled to receive upon the consummation of such Corporate Event had the Warrant
  been exercised for one Warrant Share immediately prior to consummation of such
  Corporate Event. If holders of Common Stock are given any choice as to the
  securities, cash or property to be received in a Corporate Event, then the
  Holder shall be given the same choice as to the consideration it receives upon
  any exercise of this Warrant following consummation of such Corporate Event.
  The provisions of this Section 4(b) shall apply similarly and equally to successive
  Fundamental Transactions and Corporate Events and shall be applied without
  regard to any limitations on the exercise of this Warrant in Section 1(h).
  Notwithstanding the foregoing, in the event of a Fundamental Transaction, at
  the request of the Holder delivered before the 15th calendar day after consummation
  of such Fundamental Transaction, the Company (or the Successor Entity) shall
  purchase this Warrant from the Holder by paying to the Holder, within five
  (5) Business Days after such request (or, if later, within one Business Day
  after the effective date of such Corporate Event), cash in an amount equal
  to the Black Scholes Value of the remaining unexercised portion of this Warrant
  on the date of consummation of such Fundamental Transaction. In the event a
  Corporate Event is consummated before the Complete Response Date, then the
  Exercise Price hereunder shall for all purposes thereafter be the Weighted
  Average Price for the Common Stock for the five (5) Trading Days immediately
  preceding the first public announcement of such Corporate Event; provided, however,
  that in no event shall the Exercise Price determined in accordance with this
  sentence (i) exceed $10.46 or (ii) be less than $1.57, in each case
  subject to appropriate adjustment in the event of any stock dividend, stock
  split, combination or other similar recapitalization with respect to the Common
Stock. 

       5.  NONCIRCUMVENTION.  The Company hereby covenants and agrees that the Company will
not, by amendment of its Certificate of Incorporation, Bylaws or through any reorganization, transfer of assets, consolidation, merger, scheme of arrangement, dissolution,

issue or sale of securities, or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, and will at all times in good faith comply with all the provisions of this
Warrant. Without limiting the generality of the foregoing, the Company (i) shall not increase the par value of any shares of Common Stock receivable upon the exercise of this Warrant above the Exercise Price then in effect, (ii) shall take all such
actions as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable shares of Common Stock upon the exercise of this Warrant, and (iii) shall, so long as this Warrant is outstanding, take
all action necessary to reserve and keep available out of its authorized and unissued shares of Common Stock, solely for the purpose of effecting the exercise of this Warrant, 100% of the number of shares of Common Stock issuable upon exercise of
this Warrant then outstanding (without regard to any limitations on exercise). 

     6. WARRANT HOLDER NOT DEEMED A STOCKHOLDER.  Except as otherwise specifically provided herein, the Holder,
solely in such Person's capacity as a holder of this Warrant, shall not be entitled to vote or receive dividends or be deemed the holder of share capital of the Company for any purpose, nor shall anything contained in this Warrant be construed to
confer upon the Holder, solely in such Person's capacity as the Holder of this Warrant, any of the rights of a stockholder of the Company or any right to vote, give or withhold consent to any corporate action (whether any reorganization, issue of
stock, reclassification of stock, consolidation, merger, conveyance or otherwise), receive notice of meetings, receive dividends or subscription rights, or otherwise, prior to the issuance to the Holder of the Warrant Shares which such Person is
then entitled to receive upon the due exercise of this Warrant. In addition, nothing contained in this Warrant shall be construed as imposing any liabilities on the Holder to purchase any securities (upon exercise of this Warrant or otherwise) or as
a stockholder of the Company, whether such liabilities are asserted by the Company or by creditors of the Company.

  7. REISSUANCE OF WARRANTS. 

            (a) Transfer of Warrant. If this Warrant is to be transferred, the Holder shall surrender this Warrant to the
Company, whereupon the Company will forthwith issue and deliver upon the order of the Holder a new Warrant (in accordance with Section 7(d)), registered as the Holder may request,
representing the right to purchase the number of Warrant Shares being transferred by the Holder and, if less then the total number of Warrant Shares then underlying this Warrant is being transferred, a new Warrant (in accordance with Section 7(d))
to the Holder representing the right to purchase the number of Warrant Shares not being transferred. 

            (b) Lost, Stolen or Mutilated Warrant. Upon receipt by the Company of evidence reasonably satisfactory to the
Company of the loss, theft, destruction or mutilation of this Warrant, and, in the case of loss, theft or destruction, of any indemnification undertaking by the Holder to the Company in customary form and, in the case of mutilation, upon surrender
and cancellation of this Warrant, the Company shall execute and deliver to the Holder a new Warrant (in accordance with Section 7(d)) representing the right to purchase the Warrant Shares
then underlying this Warrant. 

            (c) Exchangeable for Multiple Warrants.  This Warrant is exchangeable, upon the surrender hereof by the Holder
at the principal office of the Company, for a new Warrant or Warrants (in accordance with Section 7(d)) representing in the aggregate the right to purchase the number of Warrant Shares then
underlying this Warrant, and each such new Warrant will represent the right to purchase such portion of such Warrant Shares as is designated by the Holder at the time of such surrender; provided, however, that no Warrants for fractional shares of
Common Stock shall be given. 

            (d) Issuance of New Warrants. Whenever the Company is required to issue a new Warrant pursuant to the terms of
this Warrant, such new Warrant (i) shall be of like tenor with this Warrant, (ii) shall represent, as indicated on the face of such new Warrant, the right to purchase the Warrant Shares then underlying this Warrant (or in the case of a new Warrant
being issued pursuant to Section 7(a) or Section 7(c), the Warrant Shares designated by the Holder which, when added to the number
of shares of Common Stock underlying the other new Warrants issued in connection with such issuance, does not exceed the number of Warrant Shares then underlying this Warrant), (iii) shall have an issuance date, as indicated on the face of such new
Warrant which is the same as the Issuance Date, and (iv) shall have the same rights and conditions as this Warrant. Notwithstanding anything to the contrary herein, in no event shall this Warrant be subdivided into more than 20 separate Warrants.

       8. NOTICES.  Whenever notice is required to be given under this Warrant, unless otherwise provided herein,
such notice shall be given in accordance with Section 6 of Annex I to the Subscription Agreement. The Company shall provide the Holder with prompt written notice of all actions taken
pursuant to this Warrant, including in reasonable detail a description of such action and the reason therefore.

       9. AMENDMENT AND WAIVER.  Except as otherwise provided herein, the provisions of this Warrant may be amended
and the Company may take any action herein 

  prohibited, or omit to perform any act herein required to be performed by it, only if the Company has obtained the written consent of the Holder. 

       10. GOVERNING LAW. This Warrant shall be governed by and construed and enforced in accordance with, and all
questions concerning the construction, validity, interpretation and performance of this Warrant shall be governed by, the internal laws of the State of New York, without giving effect to any choice of law or conflict of law provision or rule
(whether of the State of New York or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of New York. 

       11. CONSTRUCTION; HEADINGS. This Warrant shall be deemed to be jointly drafted by the Company and the Holder
and shall not be construed against any person as the drafter hereof. The headings of this Warrant are for convenience of reference and shall not form part of, or affect the interpretation of, this Warrant. 

       12. DISPUTE RESOLUTION. In the case of a dispute as to the determination of the Exercise Price or the
arithmetic calculation of the Warrant Shares, the Company shall submit the disputed determinations or arithmetic calculations via facsimile within two (2) Business Days of receipt of the Exercise Notice giving rise to such dispute (or, if such
dispute has not arisen by such time or in such context, within two (2) Business Days after such dispute has arisen) to the Holder.  If the Holder and the Company are unable to agree upon such determination or calculation of the Exercise Price or the
Warrant Shares within three Business Days of such disputed determination or arithmetic calculation being submitted to the Holder, then the Company shall, within two (2) Business Days thereafter submit via facsimile (a) the disputed determination of
the Exercise Price to an independent, reputable investment bank selected by the Company and approved by the Holder or (b) the disputed arithmetic calculation of the Warrant Shares to the Company's independent, outside accountant. The Company shall
cause at its expense the investment bank or the accountant, as the case may be, to perform the determinations or calculations and notify the Company and the Holder of the results no later than ten Business Days from the time it receives the disputed
determinations or calculations. Such investment bank's or accountant's determination or calculation, as the case may be, shall be binding upon all parties absent demonstrable error. 

       13. REMEDIES, OTHER OBLIGATIONS, BREACHES AND INJUNCTIVE RELIEF.  The remedies
provided in this Warrant shall be cumulative and in addition to all other remedies available under this Warrant, at law or in equity (including a decree of specific performance and/or other injunctive relief), and nothing herein shall limit the
right of the Holder to pursue actual damages for any failure by the Company to comply with the terms of this Warrant.

     14. TRANSFER. Subject to applicable law, this Warrant may be offered for sale, sold, transferred or assigned
without the consent of the Company. 

       15. CERTAIN DEFINITIONS. For purposes of this Warrant, the following terms shall have the following meanings:

            (a) “Black Scholes Value” means the value of this Warrant based on the Black and
Scholes Option Pricing Model obtained from the “OV" function on Bloomberg using
(i) a price per share of Common Stock equal to the Weighted Average Price of
the Common Stock for the Trading Day immediately preceding the date of consummation
of the applicable Fundamental Transaction, (ii) a risk-free interest rate corresponding
to the U.S. Treasury rate for a period equal to the remaining term of this Warrant
as of the date of consummation of the applicable Fundamental Transaction and
(iii) an expected volatility equal to the greater of 100% and the 30-day volatility
obtained from the HVT function on Bloomberg determined as of the Trading Day
immediately following the public announcement of the applicable Fundamental Transaction. 

            (b) “Bloomberg” means
Bloomberg Financial Markets. 

            (c) “Business Day” means
  any day other than Saturday, Sunday or other day on which commercial banks
in The City of New York are authorized or required by law to remain closed. 

            (d) “Closing Sale Price” means, for any security as of any date, the last closing
trade price for such security on the Principal Market, as reported by Bloomberg, or, if the Principal Market begins to operate on an extended hours basis and does not designate the closing trade price, then the last bid price or the last trade
price, respectively, of such security prior to 4:00:00 p.m., New York time, as reported by Bloomberg, or, if the Principal Market is not the principal securities exchange or trading market for such security, the last closing trade price of such
security on the principal securities exchange or trading market where such security is listed or traded as reported by Bloomberg, or if the foregoing do not apply, the last closing trade price of such security in the over-the-counter market on the
electronic bulletin board for such security as reported by Bloomberg, or, if no closing trade price is reported for such security by Bloomberg, the average of the bid prices, or the ask prices, respectively, of any market makers for such security as
reported in the “pink sheets" by Pink Sheets LLC (formerly the National Quotation
Bureau, Inc.). If the Closing Sale Price cannot be calculated for a security
on a particular date on any of the foregoing bases, the Closing Sale Price of
such security on such date shall be the fair market value as mutually determined
by the Company and the Holder. If the Company and the Holder are unable to agree
upon the fair market value of such security, then such dispute shall be resolved
pursuant to Section 12 with the term “Closing Sale Price” being substituted for the term“Exercise Price." All
such determinations to be appropriately adjusted for any stock dividend, stock
split, stock combination or other similar transaction during the applicable calculation
period. 

            (e) “Common Stock” means (i) the Company's shares of Common Stock, par value
$0.01 per share, and (ii) any share capital into which such Common Stock
shall have been changed or any share capital resulting from a reclassification
of such Common Stock. 

          (f) “Convertible Securities” means
any stock or securities (other than Options) directly or indirectly convertible
into or exercisable or exchangeable for shares of Common Stock. 

          (g) “Eligible Market” means
  the Principal Market, The New York Stock Exchange, Inc., The American Stock
Exchange, The NASDAQ Global Select Market or The NASDAQ Capital Market. 

          (h) “Expiration Date” means
  (a) in the event the Complete Response Letter constitutes approval or rejection
  by the FDA of the BLA, the date that is nine (9) months after the Complete
  Response Date and (b) in the event the Complete Response Letter does not constitute
  approval or rejection by the FDA of the BLA, the earlier of (1) the date that
  is fifteen (15) months after the Complete Response Date and (2) the date that is nine (9) months after the date on
  which the Company publicly announces that it has addressed all items required
  by the FDA to be addressed before the BLA can be approved as outlined in the
  Complete Response Letter; provided, however, that if any such date falls on
  a day other than a Business Day or on which trading does not take place on
  the Principal Market (a“Holiday"), the next date that is not a Holiday.
  Notwithstanding anything to the contrary herein, this Warrant shall terminate
  and be of no further force and effect if the Complete Response Date has not
occurred on or prior to the seventh anniversary of the date hereof. 

            (i) “Fundamental Transaction” means that the Company shall, directly or indirectly, in one or more related transactions, (i) consolidate or merge with or into (whether or not the Company is the surviving corporation) another Person, or sell,
assign, transfer, convey or otherwise dispose of all or substantially all of the properties or assets of the Company to another Person, or (ii) allow another Person to make a purchase, tender or exchange offer that is accepted by the holders of more
than the 50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the Person or Persons making or party to, or associated or affiliated with the Persons making or party to, such purchase, tender or exchange
offer), or (iii) consummate a stock purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person whereby such other Person acquires more
than the 50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock purchase
agreement or other business combination), or (iv) any“person" or“group" (as these terms are used for purposes of Sections 13(d) and 14(d) of the Exchange Act) is or shall become the “beneficial owner" (as
defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of 50%
of the aggregate ordinary voting power represented by issued and outstanding
Common Stock. 

            (j) “Options” means any rights, warrants or options to subscribe for or purchase
shares of Common Stock or Convertible Securities. 

            (k) “Parent Entity” of a Person means an entity that, directly or indirectly, controls
  the applicable Person and whose common stock or equivalent equity security
  is quoted or listed on an Eligible Market, or, if there is more than one such
Person or Parent

  Entity, the Person or Parent Entity with the largest public market capitalization as of the date of consummation of the Fundamental Transaction. 

            (l) “Person” means
  an individual, a limited liability company, a partnership, a joint venture,
  a corporation, a trust, an unincorporated organization, any other entity and
a government or any department or agency thereof. 

            (m) “Principal Market” means
The NASDAQ Global Market. 

            (n) “Successor Entity” means
  the Person (or, if so elected by the Holder, the Parent Entity) formed by,
  resulting from or surviving any Fundamental Transaction or the Person (or,
  if so elected by the Holder, the Parent Entity) with which such Fundamental
Transaction shall have been entered into. 

            (o) “Trading Day” means
  any day on which the Common Stock are traded on the Principal Market, or, if
  the Principal Market is not the principal trading market for the Common Stock,
  then on the principal securities exchange or securities market on which the
  Common Stock are then traded; provided that“Trading Day" shall not
  include any day on which the Common Stock are scheduled to trade on such exchange
  or market for less than 4.5 hours or any day that the Common Stock are suspended
  from trading during the final hour of trading on such exchange or market (or
  if such exchange or market does not designate in advance the closing time of
  trading on such exchange or market, then during the hour ending at 4:00:00
p.m., New York time). 

            (p) “Weighted Average Price” means, for any security as of any date, the dollar
volume-weighted average price for such security on the Principal Market during the period beginning at 9:30:01 a.m., New York City time, and ending at 4:00:00 p.m., New York City time, as reported by Bloomberg through its“Volume at Price" function
or, if the foregoing does not apply, the dollar volume-weighted average price of such security in the over-the-counter market on the electronic bulletin board for such security during the period beginning at 9:30:01 a.m., New York City time, and
ending at 4:00:00 p.m., New York City time, as reported by Bloomberg, or, if no dollar volume-weighted average price is reported for such security by Bloomberg for such hours, the average of the highest closing bid price and the lowest closing ask
price of any of the market makers for such security as reported in the “pink sheets" by
Pink Sheets LLC (formerly the National Quotation Bureau, Inc.). If the Weighted
Average Price cannot be calculated for such security on such date on any of the
foregoing bases, the Weighted Average Price of such security on such date shall
be the fair market value as mutually determined by the Company and the Holder.
If the Company and the Holder are unable to agree upon the fair market value
of such security, then such dispute shall be resolved pursuant to Section 11 with
the term“Weighted Average Price" being substituted for the term“Exercise Price." All
such determinations shall be appropriately adjusted for any share dividend, share
split or other similar transaction during such period. 

  [Signature Page Follows] 

 IN WITNESS WHEREOF, the Company has caused this Warrant to Purchase Common Stock to be duly executed as of the Issuance Date set out above. 

	 	
      SAVIENT PHARMACEUTICALS, INC.

	 	 
	 	By:                                        
	 	Name:
	 	Title:

 

 

 EXHIBIT A 

EXERCISE NOTICE 

TO BE EXECUTED BY THE REGISTERED HOLDER TO EXERCISE THIS
WARRANT TO PURCHASE COMMON STOCK 

SAVIENT PHARMACEUTICALS, INC. 

     The undersigned holder hereby exercises the right to purchase _________________ of the shares of Common Stock (“Warrant Shares") of SAVIENT PHARMACEUTICALS, INC, a Delaware corporation (the “Company”), evidenced by the
attached Warrant to Purchase Common Stock (the “Warrant"). Capitalized terms used herein and not otherwise defined shall have the respective meanings set forth in the Warrant.
The terms of this Exercise Notice are subject to adjustment as a result of the Company’s right pursuant to Section 1(a) to require that an exercise be on a Cashless Exercise Basis. 

      1. Form of Exercise Price. The Holder intends that payment of the Exercise Price shall be made as: 

           ____________
a “Cash Exercise” with
respect to _________________ Warrant Shares; and/or 

            ____________ a “Cashless Exercise” with respect to _______________ Warrant Shares. 

      2.  Payment of Exercise Price.  In the event that the holder has elected a Cash Exercise with respect to some or all of the Warrant Shares to be issued pursuant hereto, the holder shall pay the Aggregate Exercise Price in
the sum of $ ___________________ to the Company in accordance with the terms of the Warrant. 

      3. Delivery of Warrant Shares. The Company shall deliver to the holder __________ Warrant Shares in accordance with the terms of the Warrant. 

Date: _______________ __, ______ 

___________________________________

Name of Registered Holder 

By:                                                       

     Name:

     Title: 

  ACKNOWLEDGMENT 

       The Company
  hereby acknowledges this Exercise Notice and hereby directs American Stock
  Transfer & Trust Company to issue the above indicated number of shares of Common Stock in accordance with the
Transfer Agent Instructions dated April 8, 2009 from the Company and acknowledged and agreed to by American Stock Transfer & Trust
Company. 

SAVIENT PHARMACEUTICALS, INC 

By:                                                       

     Name:

     Title:EX-4.10

Exhibit 4.10

AMICUS THERAPEUTICS, INC.

and

                                                            , as Trustee

INDENTURE

Dated as of                     ,                     

 

 

TABLE OF CONTENTS

	 	 	 	 	 
	 	 	Page	 
	 
	 	 	 	 
	ARTICLE 1 DEFINITIONS AND INCORPORATION BY REFERENCE
	 	 	1	 
	1.1. DEFINITIONS
	 	 	1	 
	1.2. OTHER DEFINITIONS
	 	 	5	 
	1.3. INCORPORATION BY REFERENCE OF TRUST INDENTURE ACT
	 	 	6	 
	1.4. RULES OF CONSTRUCTION
	 	 	6	 
	 
	 	 	 	 
	ARTICLE 2 THE SECURITIES
	 	 	7	 
	2.1. ISSUABLE IN SERIES
	 	 	7	 
	2.2. ESTABLISHMENT OF TERMS OF SERIES OF SECURITIES
	 	 	7	 
	2.3. EXECUTION AND AUTHENTICATION
	 	 	9	 
	2.4. REGISTRAR AND PAYING AGENT
	 	 	10	 
	2.5. PAYING AGENT TO HOLD ASSETS IN TRUST
	 	 	11	 
	2.6. SECURITYHOLDER LISTS
	 	 	12	 
	2.7. TRANSFER AND EXCHANGE
	 	 	12	 
	2.8. REPLACEMENT SECURITIES
	 	 	13	 
	2.9. OUTSTANDING SECURITIES
	 	 	13	 
	2.10. WHEN TREASURY SECURITIES DISREGARDED; DETERMINATION OF HOLDERS’ ACTION
	 	 	13	 
	2.11. TEMPORARY SECURITIES
	 	 	14	 
	2.12. CANCELLATION
	 	 	14	 
	2.13. PAYMENT OF INTEREST; DEFAULTED INTEREST; COMPUTATION OF INTEREST
	 	 	14	 
	2.14. CUSIP NUMBER
	 	 	15	 
	2.15. PROVISIONS FOR GLOBAL SECURITIES
	 	 	15	 
	2.16. PERSONS DEEMED OWNERS
	 	 	16	 
	 
	 	 	 	 
	ARTICLE 3 REDEMPTION
	 	 	17	 
	3.1. NOTICES TO TRUSTEE
	 	 	17	 
	3.2. SELECTION BY TRUSTEE OF SECURITIES TO BE REDEEMED
	 	 	17	 
	3.3. NOTICE OF REDEMPTION
	 	 	17	 
	3.4. EFFECT OF NOTICE OF REDEMPTION
	 	 	18	 
	3.5. DEPOSIT OF REDEMPTION PRICE
	 	 	19	 
	3.6. SECURITIES REDEEMED IN PART
	 	 	19	 

-i-

 

TABLE OF CONTENTS

(continued)

	 	 	 	 	 
	 	 	Page	 
	 
	 	 	 	 
	ARTICLE 4 COVENANTS
	 	 	19	 
	4.1. PAYMENT OF SECURITIES
	 	 	19	 
	4.2. SEC REPORTS
	 	 	19	 
	4.3. WAIVER OF STAY, EXTENSION OR USURY LAWS
	 	 	20	 
	4.4. COMPLIANCE CERTIFICATE
	 	 	20	 
	4.5. CORPORATE EXISTENCE
	 	 	21	 
	 
	 	 	 	 
	ARTICLE 5 SUCCESSOR CORPORATION
	 	 	21	 
	5.1. LIMITATION ON CONSOLIDATION, MERGER AND SALE OF ASSETS
	 	 	21	 
	5.2. SUCCESSOR PERSON SUBSTITUTED
	 	 	22	 
	 
	 	 	 	 
	ARTICLE 6 DEFAULTS AND REMEDIES
	 	 	22	 
	6.1. EVENTS OF DEFAULT
	 	 	22	 
	6.2. ACCELERATION
	 	 	23	 
	6.3. REMEDIES
	 	 	24	 
	6.4. WAIVER OF PAST DEFAULTS AND EVENTS OF DEFAULT
	 	 	24	 
	6.5. CONTROL BY MAJORITY
	 	 	24	 
	6.6. LIMITATION ON SUITS
	 	 	25	 
	6.7. RIGHTS OF HOLDERS TO RECEIVE PAYMENT
	 	 	25	 
	6.8. COLLECTION SUIT BY TRUSTEE
	 	 	25	 
	6.9. TRUSTEE MAY FILE PROOFS OF CLAIM
	 	 	26	 
	6.10. PRIORITIES
	 	 	26	 
	6.11. UNDERTAKING FOR COSTS
	 	 	26	 
	 
	 	 	 	 
	ARTICLE 7 TRUSTEE
	 	 	27	 
	7.1. DUTIES OF TRUSTEE
	 	 	27	 
	7.2. RIGHTS OF TRUSTEE
	 	 	28	 
	7.3. INDIVIDUAL RIGHTS OF TRUSTEE
	 	 	29	 
	7.4. TRUSTEE’S DISCLAIMER
	 	 	29	 
	7.5. NOTICE OF DEFAULT
	 	 	29	 
	7.6. REPORTS BY TRUSTEE TO HOLDERS
	 	 	30	 
	7.7. COMPENSATION AND INDEMNITY
	 	 	30	 

-ii-

 

TABLE OF CONTENTS

(continued)

	 	 	 	 	 
	 	 	Page	 
	 
	 	 	 	 
	7.8. REPLACEMENT OF TRUSTEE
	 	 	31	 
	7.9. SUCCESSOR TRUSTEE BY CONSOLIDATION, MERGER OR CONVERSION
	 	 	32	 
	7.10. ELIGIBILITY; DISQUALIFICATION
	 	 	32	 
	7.11. PREFERENTIAL COLLECTION OF CLAIMS AGAINST COMPANY
	 	 	32	 
	7.12. PAYING AGENTS
	 	 	32	 
	 
	 	 	 	 
	ARTICLE 8 AMENDMENTS, SUPPLEMENTS AND WAIVERS
	 	 	33	 
	8.1. WITHOUT CONSENT OF HOLDERS
	 	 	33	 
	8.2. WITH CONSENT OF HOLDERS
	 	 	33	 
	8.3. COMPLIANCE WITH TRUST INDENTURE ACT
	 	 	35	 
	8.4. REVOCATION AND EFFECT OF CONSENTS
	 	 	35	 
	8.5. NOTATION ON OR EXCHANGE OF SECURITIES
	 	 	35	 
	8.6. TRUSTEE TO SIGN AMENDMENTS, ETC
	 	 	36	 
	 
	 	 	 	 
	ARTICLE 9 DISCHARGE OF INDENTURE; DEFEASANCE
	 	 	36	 
	9.1. DISCHARGE OF INDENTURE
	 	 	36	 
	9.2. LEGAL DEFEASANCE
	 	 	36	 
	9.3. COVENANT DEFEASANCE
	 	 	37	 
	9.4. CONDITIONS TO LEGAL DEFEASANCE OR COVENANT DEFEASANCE
	 	 	37	 
	9.5. DEPOSITED MONEY AND U.S. AND FOREIGN GOVERNMENT OBLIGATIONS TO BE HELD
IN TRUST; OTHER MISCELLANEOUS PROVISIONS
	 	 	39	 
	9.6. REINSTATEMENT
	 	 	39	 
	9.7. MONEYS HELD BY PAYING AGENT
	 	 	39	 
	9.8. MONEYS HELD BY TRUSTEE
	 	 	40	 
	 
	 	 	 	 
	ARTICLE 10 MISCELLANEOUS
	 	 	40	 
	10.1. TRUST INDENTURE ACT CONTROLS
	 	 	40	 
	10.2. NOTICES
	 	 	40	 
	10.3. COMMUNICATIONS BY HOLDERS WITH OTHER HOLDERS
	 	 	42	 
	10.4. CERTIFICATE AND OPINION AS TO CONDITIONS PRECEDENT
	 	 	42	 
	10.5. STATEMENT REQUIRED IN CERTIFICATE AND OPINION
	 	 	42	 

-iii-

 

TABLE OF CONTENTS

(continued)

	 	 	 	 	 
	 	 	Page	 
	 
	 	 	 	 
	10.6. RULES BY TRUSTEE AND AGENTS
	 	 	42	 
	10.7. BUSINESS DAYS; LEGAL HOLIDAYS; PLACE OF PAYMENT
	 	 	43	 
	10.8. GOVERNING LAW
	 	 	43	 
	10.9. NO ADVERSE INTERPRETATION OF OTHER AGREEMENTS
	 	 	43	 
	10.10. SUCCESSORS
	 	 	43	 
	10.11. MULTIPLE COUNTERPARTS
	 	 	43	 
	10.12. TABLE OF CONTENTS, HEADINGS, ETC
	 	 	44	 
	10.13. SEVERABILITY
	 	 	44	 
	10.14. SECURITIES IN A FOREIGN CURRENCY OR IN EUROS
	 	 	44	 
	10.15. JUDGMENT CURRENCY
	 	 	45	 

-iv-

 

CROSS-REFERENCE TABLE

	 	 	 
	TIA SECTION	 	INDENTURE SECTION
	310(a)(1)(2)(5)

	 	7.10
	310(a)(3)(4)

	 	Inapplicable
	310(b)

	 	7.8; 7.10
	310(c)

	 	Inapplicable
	311(a)(b)

	 	7.11
	311(c)

	 	Inapplicable
	312(a)

	 	2.6
	312(b)(c)

	 	10.3
	313(a)(b)

	 	7.6
	313(c)

	 	7.6; 10.2
	313(d)

	 	7.6
	314(a)

	 	4.2; 4.4; 10.2
	314(b)

	 	N/A
	314(c)(1)(2)

	 	10.4; 10.5
	314(c)(3)

	 	Inapplicable
	314(d)

	 	Inapplicable
	314(e)

	 	10.5
	314(f)

	 	Inapplicable
	315(a)

	 	7.1, 7.2
	315(b)

	 	7.5; 10.2
	315(c)

	 	7.1
	315(d)

	 	7.1; 7.2
	315(e)

	 	6.11
	316(a)(last sentence)

	 	2.10
	316(a)(1)(A)

	 	6.5
	316(a)(1)(B)

	 	6.4
	316(a)(2)

	 	8.2
	316(b)

	 	6.7
	316(c)

	 	8.4
	317(a)(1)

	 	6.8
	317(a)(2)

	 	6.9
	317(b)

	 	2.5; 7.12
	318(a)

	 	10.1

Note: This Cross-Reference Table shall not, for any purpose, be deemed to be a part of the
Indenture.

-v-

 

     INDENTURE, dated as of     
                      
                      
            ,           
          , by and between Amicus Therapeutics,
Inc., a Delaware corporation, as Issuer (the “Company”) and            
                      
                      
     , a
                      
                      
                 organized under the laws of  
                                                           , as Trustee (the
“Trustee”).

RECITALS OF THE COMPANY

     The Company has duly authorized the execution and delivery of this Indenture to provide for
the issuance from time to time of its debentures, notes or other evidences of indebtedness to be
issued in one or more series (the “Securities”), as herein provided, up to such principal amount as
may from time to time be authorized in or pursuant to one or more resolutions of the Board of
Directors or by supplemental indenture.

     All things necessary to make this Indenture a valid agreement of the Company in accordance
with its terms have been done, and the execution and delivery thereof have been in all respects
duly authorized by the parties hereto.

NOW, THEREFORE, THIS INDENTURE WITNESSETH:

     For and in consideration of the premises and the purchase of the Securities by the Holders
thereof, it is mutually agreed, for the equal and proportionate benefit of all Holders of the
Securities of a Series thereof, as follows:

ARTICLE 1

DEFINITIONS AND INCORPORATION BY REFERENCE

     1.1. DEFINITIONS.

     “Affiliate” of any specified Person means any other Person which, directly or indirectly
through one or more intermediaries, controls, or is controlled by or is under common control with,
such specified Person. For the purposes of this definition, “control” (including, with correlative
meanings, the terms “controlling,” “controlled by” and “under common control with”), as used with
respect to any Person, means the possession, directly or indirectly, of the power to direct or
cause the direction of the management or policies of such Person, whether through the ownership of
voting securities, by agreement or otherwise.

     “Agent” means any Registrar, Paying Agent, co-registrar or agent for service of notices and
demands.

     “Board of Directors” means the Board of Directors of the Company or any committee duly
authorized to act therefor.

     “Board Resolution” means a copy of a resolution certified pursuant to an Officers’ Certificate
to have been duly adopted by the Board of Directors of the Company and to be in full force and
effect on the date of such certification which has been delivered to the Trustee.

 

 

     “Capital Stock” means, with respect to any Person, any and all shares or other equivalents
(however designated) of capital stock, partnership interests or any other participation, right or
other interest in the nature of an equity interest in such Person or any option, warrant or other
security convertible into any of the foregoing.

     “Company” means the party named as such in the first paragraph of this Indenture until a
successor replaces such party pursuant to Article 5 of this Indenture, and thereafter means the
successor and any other primary obligor on the Securities.

     “Company Order” means a written order signed in the name of the Company by two of the
Company’s executive Officers, one of whom must be its Chief Executive Officer or its Chief
Financial Officer.

     “Company Request” means any written request signed in the name of the Company by its Chief
Executive Officer, its President, any Vice President, its Chief Financial Officer or its Treasurer
and attested to by its Secretary or any Assistant Secretary.

     “Corporate Trust Office” means the office of the Trustee at which at any particular time its
corporate trust business shall be principally administered.

     “Default” means any event that is, or that with the passing of time or giving of notice or
both would be, an Event of Default.

     “Depository” means, with respect to the Securities of any Series issuable or issued in whole
or in part in the form of one or more Global Securities, the Person designated as Depository for
such Series by the Company, which Depository shall be a clearing agency registered under the
Exchange Act, until a successor Depository shall have become such pursuant to the applicable
provisions of this Indenture, and thereafter “Depository” shall mean each Person who is then a
Depository hereunder, and if at any time there is more than one such Person, such Persons.

     “Dollars” means the currency of the United States of America.

     “Euro” means the single currency of participating member states of the economic and monetary
union as contemplated in the Treaty on European Union.

     “Exchange Act” means the Securities Exchange Act of 1934, as amended.

     “Foreign Currency” means any currency or currency unit issued by a government other than the
government of the United States of America.

     “Foreign Government Obligations” means, with respect to Securities that are denominated in a
Foreign Currency, (i) direct obligations of the government that issued or caused to be issued such
currency for the payment of which obligations its full faith and credit is pledged or (ii)
obligations of a Person controlled or supervised by, or acting as an agency or instrumentality of,
such government, the timely payment of which is unconditionally guaranteed as a full faith and
credit obligation by such government, which, in either case under clauses (i) and (ii), are not
callable or redeemable at the option of the issuer thereof.

-2-

 

     “GAAP” means generally accepted accounting principles consistently applied as in effect in the
United States of America from time to time.

     “Global Security” or “Global Securities” means a Security or Securities, as the case may be,
in the form established pursuant to Section 2.2, evidencing all or part of a Series of Securities
issued to the Depository for such Series or its nominee, and registered in the name of such
Depository or nominee, and bearing the legend set forth in Section 2.15(c) (or such other legend(s)
as may be applied to such Securities in accordance with Section 2.2(24)).

     “Holder” or “Securityholder” means the Person in whose name a Security is registered on the
Registrar’s books.

     “Indebtedness” means (without duplication), with respect to any Person, any indebtedness at
any time outstanding, secured or unsecured, contingent or otherwise, which is for borrowed money
(whether or not the recourse of the lender is to the whole of the assets of such Person or only to
a portion thereof), or evidenced by bonds, notes, debentures or similar instruments, or
representing the balance deferred and unpaid of the purchase price of any property (excluding any
balances that constitute accounts payable or trade payables, and other accrued liabilities arising
in the ordinary course of business), if and to the extent any of the foregoing indebtedness would
appear as a liability upon a balance sheet of such Person prepared in accordance with GAAP.

     “Indenture” means this Indenture as amended, restated or supplemented from time to time.

     “Interest Payment Date,” when used with respect to any Security, means the Stated Maturity of
an installment of interest on such Security.

     “Lien” means, with respect to any property or assets of any Person, any mortgage or deed of
trust, pledge, hypothecation, assignment, deposit arrangement, security interest, lien, charge,
easement, encumbrance, preference, priority or other security agreement or preferential arrangement
of any kind or nature whatsoever on or with respect to such property or assets (including, without
limitation, any capitalized lease obligation, conditional sales or other title retention agreement
having substantially the same economic effect as any of the foregoing).

     “Maturity,” when used with respect to any Security, means the date on which the principal of
such Security, or an installment of principal, becomes due and payable as therein or herein
provided, whether at the Stated Maturity or by declaration of acceleration, call for redemption,
notice of option to elect payment or otherwise.

     “Officer” means the Chief Executive Officer, the President, any Vice President, the Chief
Financial Officer, the Treasurer or the Secretary of the Company, or any other officer designated
by the Board of Directors, as the case may be.

     “Officers’ Certificate” means, with respect to any Person, a certificate signed by the
Chairman, Chief Executive Officer, President or any Senior or Executive Vice President and the
Chief Financial Officer or any Treasurer of such Person, that shall comply with applicable
provisions of this Indenture.

-3-

 

     “Opinion of Counsel” means a written opinion from legal counsel, which counsel is reasonably
acceptable to the Trustee. The counsel may be an employee of or counsel to the Company.

     “Person” means any individual, corporation, limited liability company, partnership, joint
venture, association, joint-stock company, trust, unincorporated organization or government
(including any agency or political subdivision thereof).

     “Redemption Date,” when used with respect to any Security to be redeemed, means the date fixed
for such redemption pursuant to this Indenture.

     “Responsible Officer,” when used with respect to the Trustee, means any officer within the
corporate trust department or division of the Trustee (or any successor group of the Trustee) or
any other officer of the Trustee customarily performing functions similar to those performed by any
of the above designated officers, and also means, with respect to a particular corporate trust
matter, any other officer to whom such matter is referred because of his knowledge of and
familiarity with the particular subject.

     “SEC” means the United States Securities and Exchange Commission as constituted from time to
time, or any successor performing substantially the same functions.

     “Securities” means the securities that are issued under this Indenture, as amended or
supplemented from time to time pursuant to this Indenture.

     “Securities Act” means the Securities Act of 1933, as amended.

     “Series” or “Series of Securities” means each series of debentures, notes or other debt
instruments of the Company created pursuant to Sections 2.1 and 2.2.

     “Significant Subsidiary” means (i) any direct or indirect Subsidiary of the Company that would
be a “significant subsidiary” as defined in Article 1, Rule 1-02 of Regulation S-X, promulgated
pursuant to the Securities Act, as such regulation is in effect on the date hereof, or (ii) any
group of direct or indirect Subsidiaries of the Company that, taken together as a group, would be a
“significant subsidiary” as defined in Article 1, Rule 1-02 of Regulation S-X, promulgated pursuant
to the Securities Act, as such regulation is in effect on the date hereof.

     “Stated Maturity,” when used with respect to any Security or any installment of principal
thereof or interest thereon, means the date specified in such Security as the fixed date on which
the principal of such Security, or such installment of principal or interest, is due and payable,
and when used with respect to any other Indebtedness, means the date specified in the instrument
governing such Indebtedness as the fixed date on which the principal of such Indebtedness, or any
installment of interest thereon, is due and payable.

     “Subsidiary” of any specified Person means any corporation, limited liability company,
partnership, joint venture, association or other business entity, whether now existing or hereafter
organized or acquired, (i) in the case of a corporation, of which more than 50% of the total voting
power of the Capital Stock entitled (without regard to the occurrence of any contingency) to vote
in the election of directors thereof is held, directly or indirectly, by such Person or any of

-4-

 

its Subsidiaries; or (ii) in the case of a partnership, joint venture, association or other
business entity, with respect to which such Person or any of its Subsidiaries has the power to
direct or cause the direction of the management and policies of such entity by contract or
otherwise, or if in accordance with GAAP such entity is consolidated with such Person for financial
statement purposes.

     “TIA” means the Trust Indenture Act of 1939 (15 U.S. Code Section 77aaa-77bbbb) as in effect
on the date of this Indenture (except as provided in Section 8.3).

     “Trustee” means the party named as such in this Indenture until a successor replaces it
pursuant to this Indenture, and thereafter means the successor, and if at any time there is more
than one such Person, “Trustee” as used with respect to the Securities of any Series shall mean the
Trustee with respect to Securities of that Series.

     “U.S. Government Obligations” means direct non-callable obligations of, or non-callable
obligations guaranteed by, the United States of America for the payment of which obligation or
guarantee the full faith and credit of the United States of America is pledged.

     1.2. OTHER DEFINITIONS.

     The definitions of the following terms may be found in the sections indicated as follows:

	 	 	 
	TERM	 	DEFINED IN SECTION
	“Bankruptcy Law”

	 	 6.1
	“Business Day”

	 	 10.7
	“Covenant Defeasance”

	 	 9.3
	“Custodian”

	 	 6.1
	“Event of Default”

	 	 6.1
	“Journal”

	 	 10.15
	“Judgment Currency”

	 	 10.16
	“Legal Defeasance

	 	 9.2
	“Legal Holiday”

	 	 10.7
	“Market Exchange Rate”

	 	 10.15
	“New York Paying Agent”

	 	 2.4
	“Paying Agent”

	 	 2.4
	“Place of Payment”

	 	 10.7
	“Registrar”

	 	 2.4
	“Required Currency”

	 	 10.16
	“Service Agent”

	 	 2.4

-5-

 

     1.3. INCORPORATION BY REFERENCE OF TRUST INDENTURE ACT.

     Whenever this Indenture refers to a provision of the TIA, the portion of such provision
required to be incorporated herein in order for this Indenture to be qualified under the TIA is
incorporated by reference in and made a part of this Indenture. The following TIA terms used in
this Indenture have the following meanings:

     “Commission” means the SEC.

     “indenture securities” means the Securities.

     “indenture securityholder” means a Holder or Securityholder.

     “indenture to be qualified” means this Indenture.

     “indenture trustee” or “institutional trustee” means the Trustee.

     “obligor on the indenture securities” means the Company.

     All other terms used in this Indenture that are defined by the TIA, defined in the TIA by
reference to another statute or defined by SEC rule have the meanings therein assigned to them.

     1.4. RULES OF CONSTRUCTION.

     Unless the context otherwise requires:

     (1) a term has the meaning assigned to it herein, whether defined expressly or by
reference;

     (2) an accounting term not otherwise defined has the meaning assigned to it in
accordance with GAAP;

     (3) “or” is not exclusive;

     (4) words in the singular include the plural, and in the plural include the singular;

     (5) words used herein implying any gender shall apply to each gender; and

     (6) the words “herein”, “hereof” and “hereunder” and other words of similar import
refer to this Indenture as a whole and not to any particular Article, Section or other
subdivision.

-6-

 

ARTICLE 2

THE SECURITIES

     2.1. ISSUABLE IN SERIES.

     The aggregate principal amount of Securities that may be authenticated and delivered under
this Indenture is $100,000,000. The Securities may be issued in one or more Series. All Securities
of a Series shall be identical except as may be set forth in a Board Resolution, a supplemental
indenture or an Officers’ Certificate detailing the adoption of the terms thereof pursuant to the
authority granted under a Board Resolution. In the case of Securities of a Series to be issued from
time to time, the Board Resolution, Officers’ Certificate or supplemental indenture may provide for
the method by which specified terms (such as interest rate, Stated Maturity, record date or date
from which interest shall accrue) are to be determined. Securities may differ between Series in
respect of any matters, PROVIDED, that all Series of Securities shall be equally and ratably
entitled to the benefits of the Indenture.

     2.2. ESTABLISHMENT OF TERMS OF SERIES OF SECURITIES.

     At or prior to the issuance of any Securities within a Series, the following shall be
established (as to the Series generally, in the case of Subsection 2.2(1) and either as to such
Securities within the Series or as to the Series generally in the case of Subsections 2.2(2)
through 2.2(24)) by a Board Resolution, a supplemental indenture or an Officers’ Certificate, in
each case, pursuant to authority granted under a Board Resolution:

     (1) the title of the Series (which shall distinguish the Securities of that particular
Series from the Securities of any other Series);

     (2) any limit upon the aggregate principal amount of the Securities of the Series which
may be authenticated and delivered under this Indenture (except for Securities authenticated
and delivered upon registration of transfer of, or in exchange for, or in lieu of, other
Securities of the Series pursuant to Section 2.7, 2.8, 2.11, 3.6 or 8.5);

     (3) the price or prices (expressed as a percentage of the principal amount thereof) at
which the Securities of the Series will be issued;

     (4) the date or dates on which the principal of the Securities of the Series is
payable;

     (5) the rate or rates (which may be fixed or variable) per annum or, if applicable, the
method used to determine such rate or rates (including, but not limited to, any commodity,
commodity index, stock exchange index or financial index) at which the Securities of the
Series shall bear interest, if any, the date or dates from which such interest, if any,
shall accrue, the date or dates on which such interest, if any, shall commence and be
payable and any regular record date for the interest payable on any Interest Payment Date;

-7-

 

     (6) the place or places where the principal of, and interest and premium, if any, on,
the Securities of the Series shall be payable, or the method of such payment, if by wire
transfer, mail or other means;

     (7) if applicable, the period or periods within which, the price or prices at which and
the terms and conditions upon which the Securities of the Series may be redeemed, in whole
or in part, at the option of the Company;

     (8) the obligation, if any, of the Company to redeem or purchase the Securities of the
Series pursuant to any sinking fund or analogous provisions or at the option of a Holder
thereof, and the period or periods within which, the price or prices at which and the terms
and conditions upon which Securities of the Series shall be redeemed or purchased, in whole
or in part, pursuant to such obligation;

     (9) the dates, if any, on which and the price or prices at which the Securities of the
Series will be repurchased by the Company at the option of the Holders thereof, and other
detailed terms and provisions of such repurchase obligations;

     (10) if other than denominations of $1,000 and any integral multiple thereof, the
denominations in which the Securities of the Series shall be issuable;

     (11) the forms of the Securities of the Series in bearer (if to be issued outside of
the United States of America) or fully registered form (and, if in fully registered form,
whether the Securities will be issuable as Global Securities);

     (12) if other than the principal amount thereof, the portion of the principal amount of
the Securities of the Series that shall be payable upon declaration of acceleration of the
Maturity thereof pursuant to Section 6.2;

     (13) the currency of denomination of the Securities of the Series, which may be Dollars
or any Foreign Currency, including, but not limited to, the Euro, and, if such currency of
denomination is a composite currency other than the Euro, the agency or organization, if
any, responsible for overseeing such composite currency;

     (14) the designation of the currency, currencies or currency units in which payment of
the principal of, and interest and premium, if any, on, the Securities of the Series will be
made;

     (15) if payments of principal of, or interest or premium, if any, on, the Securities of
the Series are to be made in one or more currencies or currency units other than that or
those in which such Securities are denominated, the manner in which the exchange rate with
respect to such payments will be determined;

     (16) the manner in which the amounts of payment of principal of, or interest and
premium, if any, on, the Securities of the Series will be determined, if such amounts may be
determined by reference to an index based on a currency or currencies or by reference to a
commodity, commodity index, stock exchange index or financial index;

-8-

 

     (17) the provisions, if any, relating to any collateral provided for the Securities of
the Series;

     (18) any addition to or change in the covenants set forth in Articles 4 or 5 that
applies to Securities of the Series;

     (19) any addition to or change in the Events of Default which applies to any Securities
of the Series, and any change in the right of the Trustee or the requisite Holders of such
Securities to declare the principal amount thereof due and payable pursuant to Section 6.2;

     (20) the terms and conditions, if any, for conversion of the Securities into or
exchange of the Securities for shares of common stock or preferred stock of the Company that
apply to Securities of the Series;

     (21) any depositories, interest rate calculation agents, exchange rate calculation
agents or other agents with respect to Securities of such Series if other than those
appointed herein;

     (22) the terms and conditions, if any, upon which the Securities shall be subordinated
in right of payment to other Indebtedness of the Company;

     (23) if applicable, that the Securities of the Series, in whole or any specified part,
shall be defeasible pursuant to Article 9; and

     (24) any other terms of the Securities of the Series (which terms shall not be
inconsistent with the provisions of this Indenture, except as permitted by Section 8.1, but
which may modify or delete any provision of this Indenture insofar as it applies to such
Series).

     All Securities of any one Series need not be issued at the same time, and may be issued from
time to time, consistent with the terms of this Indenture, if so provided by or pursuant to the
Board Resolution, supplemental indenture or Officers’ Certificate referred to above, however, the
authorized principal amount of any Series may not be increased to provide for issuances of
additional Securities of such Series, unless otherwise provided in such Board Resolution,
supplemental indenture or Officers’ Certificate.

     2.3. EXECUTION AND AUTHENTICATION.

     The Securities shall be executed on behalf of the Company by two Officers of the Company or an
Officer and an Assistant Secretary of the Company. Each such signature may be either manual or
facsimile. The Company’s seal may be impressed, affixed, imprinted or reproduced on the Securities
and may be in facsimile form.

     If an Officer whose signature is on a Security no longer holds that office at the time the
Security is authenticated, the Security shall nevertheless be valid.

-9-

 

     A Security shall not be valid until authenticated by the manual signature of the Trustee or an
authenticating agent. The signature shall be conclusive evidence that the Security has been
authenticated under this Indenture. The Trustee shall at any time, and from time to time,
authenticate Securities for original issue in the principal amount provided in the Board
Resolution, supplemental indenture hereto or Officers’ Certificate, upon receipt by the Trustee of
a Company Order. Such Company Order may authorize authentication and delivery pursuant to oral or
electronic instructions from the Company or its duly authorized agent or agents, which oral
instructions shall be promptly confirmed in writing. Each Security shall be dated the date of its
authentication.

     The aggregate principal amount of Securities of any Series outstanding at any time may not
exceed any limit upon the maximum principal amount for such Series set forth in the Board
Resolution, supplemental indenture hereto or Officers’ Certificate delivered pursuant to Section
2.2, except as provided in Section 2.8.

     Prior to the issuance of Securities of any Series, the Trustee shall have received and
(subject to Section 7.1) shall be fully protected in relying on: (a) the Board Resolution,
supplemental indenture hereto or Officers’ Certificate establishing the form of the Securities of
that Series or of Securities within that Series and the terms of the Securities of that Series or
of Securities within that Series, (b) an Officers’ Certificate complying with Section 10.4, and (c)
an Opinion of Counsel complying with Section 10.4.

     The Trustee shall have the right to decline to authenticate and deliver any Securities of any
Series: (a) if the Trustee, being advised in writing by outside counsel, determines that such
action may not lawfully be taken; or (b) if the Trustee in good faith by its board of directors or
trustees, executive committee or a trust committee of directors and/or vice-presidents shall
reasonably determine that such action would expose the Trustee to personal liability, or cause it
to have a conflict of interest with respect to Holders of any then outstanding Series of
Securities.

     The Trustee may appoint an authenticating agent acceptable to the Company to authenticate
Securities. An authenticating agent may authenticate Securities whenever the Trustee may do so. Any
appointment shall be evidenced by an instrument signed by an authorized officer of the Trustee, a
copy of which shall be furnished to the Company. Each reference in this Indenture to authentication
by the Trustee includes authentication by such agent. An authenticating agent has the same rights
as an Agent to deal with the Company or an Affiliate of the Company.

     2.4. REGISTRAR AND PAYING AGENT.

     The Company shall maintain in each Place of Payment for any Series of Securities (i) an office
or agency where such Securities may be presented for registration of transfer or for exchange
(“Registrar”), (ii) an office or agency where such Securities may be presented for payment (“Paying
Agent”) (PROVIDED that the Company shall at all times maintain a Paying Agent in the Borough of
Manhattan, City of New York, State of New York (the “New York Paying Agent”), and PROVIDED,
FURTHER, that at the option of the Company payment of interest may be made by check mailed to the
address of the Person entitled thereto as such address shall appear in the register for the
Securities maintained by the Registrar), and (iii) an

-10-

 

office or agency where notices and demands to or upon the Company in respect of the Securities
and this Indenture may be served (“Service Agent”). The Registrar shall keep a register of the
Securities and of their transfer and exchange. The Company may have one or more co-registrars and
one or more additional paying agents. The Company shall give prompt written notice to the Trustee
of the location, and any change in the location, of such office or agency. If at any time the
Company shall fail to maintain any such required office, or to furnish the Trustee with the address
thereof, such presentations, surrenders, notices and demands may be made or served at the address
of the Trustee as set forth in Section 10.2. If the Company acts as Paying Agent, it shall
segregate the money held by it for the payment of principal of, and interest and premium, if any,
on, the Securities and hold it as a separate trust fund. The Company may change any Paying Agent,
Registrar, co-registrar or any other Agent without notice to any Securityholder.

     The Company may also from time to time designate one or more other offices or agencies where
the Securities may be presented or surrendered for any or all such purposes, and may from time to
time rescind such designations; PROVIDED, HOWEVER, that no such designation or rescission shall in
any manner relieve the Company of its obligation to maintain an office or agency in each Place of
Payment for Securities of any Series for such purposes. The Company hereby initially designates the
Corporate Trust Office of the Trustee as such office of the Company. The Company shall give prompt
written notice to the Trustee of such designation or rescission, and of any change in the location
of any such other office or agency.

     The Company shall enter into an appropriate agency agreement with any Registrar or Paying
Agent not a party to this Indenture. The agreement shall implement the provisions of this Indenture
that relate to such Agent. The Company shall notify the Trustee of the name and address of any such
Agent. If the Company fails to maintain a Registrar or Paying Agent, or agent for service of
notices and demands, or fails to give the foregoing notice, the Trustee shall act as such. The
Company hereby appoints the Trustee as the initial Registrar, Paying Agent and Service Agent for
each Series unless another Registrar, Paying Agent or Service Agent, as the case may be, is
appointed prior to the time Securities of that Series are first issued. The Company designates
                    , as the New York Paying Agent, with offices at
                    .

     2.5. PAYING AGENT TO HOLD ASSETS IN TRUST.

     The Trustee as Paying Agent shall, and the Company shall require each Paying Agent other than
the Trustee to agree in writing that each Paying Agent shall, hold in trust for the benefit of the
Holders of any Series of Securities or the Trustee all assets held by the Paying Agent for the
payment of principal of, or interest or premium, if any, on, such Series of Securities (whether
such assets have been distributed to it by the Company or any other obligor on such Series of
Securities), and the Company and the Paying Agent shall notify the Trustee in writing of any
Default by the Company (or any other obligor on such Series of Securities) in making any such
payment. The Company at any time may require a Paying Agent to distribute all assets held by it to
the Trustee and account for any assets disbursed, and the Trustee may, at any time during the
continuance of any payment default with respect to any Series of Securities, upon written request
to a Paying Agent, require such Paying Agent to distribute all assets held by it to the Trustee and
to account for any assets distributed. Upon distribution to the Trustee of all

-11-

 

assets that shall have been delivered by the Company to the Paying Agent, the Paying Agent
shall have no further liability for such assets.

     2.6. SECURITYHOLDER LISTS.

     The Trustee shall preserve in as current a form as is reasonably practicable the most recent
list available to it of the names and addresses of Securityholders of each Series of Securities. If
the Trustee is not the Registrar, the Company shall furnish to the Trustee as of each regular
record date for the payment of interest on the Securities of a Series and before each related
Interest Payment Date, and at such other times as the Trustee may request in writing, a list in
such form and as of such date as the Trustee may reasonably require of the names and addresses of
Securityholders of each Series of Securities.

     2.7. TRANSFER AND EXCHANGE.

     When Securities of a Series are presented to the Registrar with a request to register the
transfer thereof, the Registrar shall register the transfer as requested if the requirements of
applicable law are met, and when such Securities of a Series are presented to the Registrar with a
request to exchange them for an equal principal amount of other authorized denominations of
Securities of the same Series, the Registrar shall make the exchange as requested. To permit
transfers and exchanges, upon surrender of any Security for registration of transfer at the office
or agency maintained pursuant to Section 2.4, the Company shall execute and the Trustee shall
authenticate Securities at the Registrar’s request.

     If Securities are issued as Global Securities, the provisions of Section 2.15 shall apply.

     All Securities issued upon any registration of transfer or exchange of Securities shall be the
valid obligations of the Company, evidencing the same debt, and entitled to the same benefits under
this Indenture, as the Securities surrendered upon such registration of transfer or exchange.

     Every Security presented or surrendered for registration of transfer or for exchange shall (if
so required by the Company or the Registrar or a co-registrar) be duly endorsed, or be accompanied
by a written instrument of transfer in form satisfactory to the Company and the Registrar or a
co-registrar, duly executed by the Holder thereof or his attorney duly authorized in writing.

     Any exchange or transfer shall be without charge, except that the Company may require payment
by the Holder of a sum sufficient to cover any tax or other governmental charge that may be imposed
in relation to a transfer or exchange, but this provision shall not apply to any exchange pursuant
to Section 2.11, 3.6 or 8.5. The Trustee shall not be required to register transfers of Securities
of any Series, or to exchange Securities of any Series, for a period of 15 days before the record
date for selection for redemption of such Securities. The Trustee shall not be required to exchange
or register transfers of Securities of any Series called or being called for redemption in whole or
in part, except the unredeemed portion of such Security being redeemed in part.

-12-

 

     2.8. REPLACEMENT SECURITIES.

     If a mutilated Security is surrendered to the Trustee, or if the Holder of a Security presents
evidence to the satisfaction of the Company and the Trustee that the Security has been lost,
destroyed or wrongfully taken, the Company shall issue and the Trustee shall authenticate a
replacement Security of the same Series and of like tenor and principal amount and bearing a number
not contemporaneously outstanding. An indemnity bond may be required by the Company or the Trustee
that is sufficient in the reasonable judgment of the Company or the Trustee, as the case may be, to
protect the Company, the Trustee or any Agent from any loss which any of them may suffer if a
Security is replaced. The Company may charge such Holder for the Company’s out-of-pocket expenses
in replacing a Security, including the fees and expenses of the Trustee. Every replacement Security
shall constitute an original additional obligation of the Company, whether or not the destroyed,
lost or stolen Security shall be at any time enforceable by anyone, and shall be entitled to all
the benefits of this Indenture equally and proportionately with any and all other Securities of
that Series duly issued hereunder.

     2.9. OUTSTANDING SECURITIES.

     Securities outstanding at any time are all Securities authenticated by the Trustee, except for
those canceled by it, those delivered to it for cancellation and those described in this Section
2.9 as not outstanding.

     If a Security is replaced pursuant to Section 2.8 (other than a mutilated Security surrendered
for replacement), it ceases to be outstanding until the Company and the Trustee receive proof
satisfactory to each of them that the replaced Security is held by a bona fide purchaser. A
mutilated Security ceases to be outstanding upon surrender of such Security and replacement thereof
pursuant to Section 2.8.

     If a Paying Agent holds on a Redemption Date or the Stated Maturity money sufficient to pay
the principal of, premium, if any, and accrued interest on, Securities payable on that date, and is
not prohibited from paying such money to the Holders thereof pursuant to the terms of this
Indenture (PROVIDED, that if such Securities are to be redeemed, notice of such redemption has been
duly given pursuant to this Indenture or provision therefor satisfactory to the Trustee has been
made), then on and after that date such Securities cease to be outstanding and interest on them
ceases to accrue.

     A Security does not cease to be outstanding solely because the Company or an Affiliate holds
the Security.

     2.10. WHEN TREASURY SECURITIES DISREGARDED; DETERMINATION OF HOLDERS’ ACTION.

     In determining whether the Holders of the required aggregate principal amount of the
Securities of any Series have concurred in any direction, waiver or consent, the Securities of any
Series owned by the Company or any other obligor on such Securities, or by any Affiliate of any of
them, shall be disregarded, except that for the purposes of determining whether the Trustee shall
be protected in relying on any such direction, waiver or consent, only Securities of such Series
which the Trustee actually knows are so owned shall be so disregarded. Securities of such

-13-

 

Series so owned which have been pledged in good faith shall not be disregarded if the pledgee
establishes to the satisfaction of the Trustee the pledgee’s right so to act with respect to the
Securities of such Series and that the pledgee is not the Company or any other obligor on the
Securities of such Series, or an Affiliate of any of them.

     2.11. TEMPORARY SECURITIES.

     Until definitive Securities are ready for delivery, the Company may prepare and execute, and
the Trustee shall authenticate, temporary Securities. Temporary Securities shall be substantially
in the form, and shall carry all rights, of definitive Securities, but may have variations that the
Company considers appropriate for temporary Securities. Without unreasonable delay, the Company
shall prepare and execute, and the Trustee shall authenticate, definitive Securities in exchange
for temporary Securities without charge to the Holder.

     2.12. CANCELLATION.

     All Securities surrendered for payment, redemption or registration of transfer or exchange, or
for credit against any sinking fund payment, shall, if surrendered to any Person other than the
Trustee, be delivered to the Trustee for cancellation. The Company may at any time deliver to the
Trustee for cancellation any Securities previously authenticated and delivered hereunder which the
Company may have acquired in any manner whatsoever, and may deliver to the Trustee (or to any other
Person for delivery to the Trustee) for cancellation any Securities previously authenticated
hereunder which the Company has not issued and sold. The Registrar and the Paying Agent shall
forward to the Trustee any Securities surrendered to them for transfer, exchange or payment. The
Trustee or, at the direction of the Trustee, the Registrar or the Paying Agent, and no one else,
shall cancel, and at the written request of the Company shall dispose of, all Securities
surrendered for transfer, exchange, payment or cancellation. If the Company shall acquire any of
the Securities, such acquisition shall not operate as a redemption or satisfaction of the
Indebtedness represented by such Securities unless and until the same are surrendered to the
Trustee for cancellation pursuant to this Section 2.12. No Securities shall be authenticated in
lieu of or in exchange for any Securities cancelled as provided in this Section 2.12, except as
expressly permitted by this Indenture.

     2.13. PAYMENT OF INTEREST; DEFAULTED INTEREST; COMPUTATION OF INTEREST.

     Except as otherwise provided as contemplated by Section 2.2 with respect to any Series of
Securities, interest on any Security which is payable, and is punctually paid or duly provided for,
on any Interest Payment Date shall be paid to the Person in whose name that Security is registered
at the close of business on the regular record date for such interest, as provided in the Board
Resolution, supplemental indenture hereto or Officers’ Certificate establishing the terms of such
Series.

     If the Company defaults in a payment of interest on the Securities, it shall pay the defaulted
amounts, plus any interest payable on defaulted amounts pursuant to Section 4.1, to the Persons who
are Securityholders on a subsequent special record date, which date shall be the 15th day next
preceding the date fixed by the Company for the payment of defaulted interest, or

-14-

 

the next succeeding Business Day if such date is not a Business Day. At least 15 days before
the special record date, the Company shall mail or cause to be mailed to each Securityholder, with
a copy to the Trustee, a notice that states the special record date, the payment date and the
amount of defaulted interest, and interest payable on such defaulted interest, if any, to be paid.

     Except as otherwise specified as contemplated by Section 2.2 for Securities of any Series,
interest on the Securities of each Series shall be computed on the basis of a 360-day year of
twelve 30-day months.

     2.14. CUSIP NUMBER.

     The Company in issuing the Securities may use one or more “CUSIP” numbers, and, if the Company
does so, the Trustee shall use the CUSIP number(s) in notices of redemption or exchange as a
convenience to Holders, PROVIDED, that any such notice may state that no representation is made as
to the correctness or accuracy of the CUSIP number(s) printed in the notice or on the Securities,
and that reliance may be placed only on the other identification numbers printed on the Securities,
and that any such redemption or exchange shall not be affected by any defect in or omission of any
such numbers.

     2.15. PROVISIONS FOR GLOBAL SECURITIES.

          (a) A Board Resolution, a supplemental indenture hereto or an Officers’ Certificate shall
establish whether the Securities of a Series shall be issued in whole or in part in the form of one
or more Global Securities, and the Depository for such Global Securities or Securities.

          (b) Notwithstanding any provisions to the contrary contained in Section 2.7 and in addition
thereto, if, and only if the Depository (i) at any time is unwilling or unable to continue as
Depository for such Global Security or ceases to be a clearing agency registered under the Exchange
Act and (ii) a successor Depository is not appointed by the Company within 90 days after the date
the Company is so informed in writing or becomes aware of the same, the Company promptly will
execute and deliver to the Trustee definitive Securities, and the Trustee, upon receipt of a
Company Request for the authentication and delivery of such definitive Securities (which the
Company will promptly execute and deliver to the Trustee) and an Officers’ Certificate to the
effect that such Global Security shall be so exchangeable, will authenticate and deliver definitive
Securities, without charge, registered in such names and in such authorized denominations as the
Depository shall direct in writing (pursuant to instructions from its direct and indirect
participants or otherwise) in an aggregate principal amount equal to the principal amount of the
Global Security with like tenor and terms. Upon the exchange of a Global Security for definitive
Securities, such Global Security shall be canceled by the Trustee. Unless and until it is exchanged
in whole or in part for definitive Securities, as provided in this Section 2.15(b), a Global
Security may not be transferred except as a whole by the Depository with respect to such Global
Security to a nominee of such Depository, by a nominee of such Depository to such Depository or
another nominee of such Depository or by the Depository or any such nominee to a successor
Depository or a nominee of such a successor Depository.

-15-

 

          (c) Any Global Security issued hereunder shall bear a legend in substantially the following
form:

     “This Security is a Global Security within the meaning of the Indenture hereinafter
referred to, and is registered in the name of the Depository or a nominee of the Depository.
This Security is exchangeable for Securities registered in the name of a Person other than
the Depository or its nominee only in the limited circumstances described in the Indenture,
and may not be transferred except as a whole by the Depository to a nominee of the
Depository, by a nominee of the Depository to the Depository or another nominee of the
Depository or by the Depository or any such nominee to a successor Depository or a nominee
of such a successor Depository.”

          (d) The Depository, as a Holder, may appoint agents and otherwise authorize participants to
give or take any request, demand, authorization, direction, notice, consent, waiver or other action
which a Holder is entitled to give or take under the Indenture.

          (e) Notwithstanding the other provisions of this Indenture, unless otherwise specified as
contemplated by Section 2.2, payment of the principal of, and interest and premium, if any, on, any
Global Security shall be made to the Depository or its nominee in its capacity as the Holder
thereof.

          (f) Except as provided in Section 2.15(e) above, the Company, the Trustee and any Agent shall
treat a Person as the Holder of such principal amount of outstanding Securities of any Series
represented by a Global Security as shall be specified in a written statement of the Depository
(which may be in the form of a participants’ list for such Series) with respect to such Global
Security, for purposes of obtaining any consents, declarations, waivers or directions required to
be given by the Holders pursuant to this Indenture, PROVIDED, that until the Trustee is so provided
with a written statement, it may treat the Depository or any other Person in whose name a Global
Security is registered as the owner of such Global Security for the purpose of receiving payment of
the principal of, and any premium and (subject to Section 2.13) any interest on, such Global
Security and for all other purposes whatsoever, and none of the Company, the Trustee or any agent
of the Company or the Trustee shall be affected by notice to the contrary.

     2.16. PERSONS DEEMED OWNERS.

     Prior to due presentment of a Security for registration of transfer, the Company, the Trustee,
the Registrar and any agent of the Company, the Registrar or the Trustee may treat the Person in
whose name such Security is registered as the owner of such Security for the purpose of receiving
payment of the principal of, and any premium and (subject to Section 2.13) any interest on, such
Security and for all other purposes whatsoever, and none of the Company, the Trustee, the Registrar
or any agent of the Company, the Trustee or the Registrar shall be affected by notice to the
contrary.

-16-

 

ARTICLE 3

REDEMPTION

     3.1. NOTICES TO TRUSTEE.

     The Company may, with respect to any Series of Securities, reserve the right to redeem and pay
the Series of Securities, or may covenant to redeem and pay the Series of Securities or any part
thereof, prior to the Stated Maturity thereof at such time and on such terms as provided for in
such Securities or the related Board Resolution, supplemental indenture or Officers’ Certificate.
If a Series of Securities is redeemable and the Company elects to redeem all or part of such Series
of Securities, it shall notify the Trustee of the Redemption Date and the principal amount of
Securities to be redeemed at least 45 days (unless a shorter notice shall be satisfactory to the
Trustee) before the Redemption Date. Any such notice may be canceled at any time prior to notice of
such redemption being mailed to any Holder, and shall thereby be void and of no effect.

     3.2. SELECTION BY TRUSTEE OF SECURITIES TO BE REDEEMED.

     Unless otherwise indicated for a particular Series of Securities by a Board Resolution, a
supplemental indenture or an Officers’ Certificate, if fewer than all of the Securities of a Series
are to be redeemed, the Trustee shall select the Securities of a Series to be redeemed pro rata, by
lot or by any other method that the Trustee considers fair and appropriate (unless the Company
specifically directs the Trustee otherwise) and, if such Securities are listed on any securities
exchange, by a method that complies with the requirements of such exchange.

     The Trustee shall make the selection from Securities of a Series outstanding and not
previously called for redemption, and shall promptly notify the Company in writing of the
Securities selected for redemption and, in the case of any Security selected for partial
redemption, the principal amount thereof to be redeemed at least 35 but not more than 60 days
before the Redemption Date. Securities of a Series in denominations of $1,000 may be redeemed only
in whole. The Trustee may select for redemption portions of the principal of Securities of a Series
that have denominations larger than $1,000. Securities of a Series and portions of them it selects
shall be in amounts of $1,000 or, with respect to Securities of any Series issuable in other
denominations pursuant to Section 2.2(10), the minimum principal denomination for each Series and
integral multiples thereof. Provisions of this Indenture that apply to Securities called for
redemption also apply to portions of Securities called for redemption.

     3.3. NOTICE OF REDEMPTION.

     Unless otherwise indicated for a particular Series by Board Resolution, a supplemental
indenture hereto or an Officers’ Certificate, at least 30 days, and no more than 60 days, before a
Redemption Date, the Company shall mail, or cause to be mailed, a notice of redemption by
first-class mail to each Holder of Securities to be redeemed at his or her last address as the same
appears on the registry books maintained by the Registrar. The notice shall identify the Securities
to be redeemed and shall state:

     (1) the Redemption Date;

-17-

 

     (2) the redemption price, and that such redemption price shall become due and payable
on the Redemption Date;

     (3) if any Security of a Series is being redeemed in part, the portion of the principal
amount of such Security of a Series to be redeemed and that, after the Redemption Date and
upon surrender of such Security of a Series, a new Security or Securities in principal
amount equal to the unredeemed portion will be issued;

     (4) the name and address of the Paying Agent;

     (5) that Securities of a Series called for redemption must be surrendered to the Paying
Agent to collect the redemption price, and the place or places where each such Security is
to be surrendered for such payment;

     (6) that, unless the Company defaults in making the redemption payment, interest on the
Securities of a Series called for redemption ceases to accrue on the Redemption Date, and
the only remaining right of the Holders of such Securities is to receive payment of the
redemption price upon surrender to the Paying Agent of the Securities redeemed;

     (7) if fewer than all of the Securities of a Series are to be redeemed, the
identification of the particular Securities of a Series (or portion thereof) to be redeemed,
as well as the aggregate principal amount of Securities of a Series to be redeemed and the
aggregate principal amount of Securities of a Series to be outstanding after such partial
redemption.

     (8) the CUSIP number, if any, printed on the Securities being redeemed; and

     (9) that no representation is made as to the correctness or accuracy of the CUSIP
number, if any, listed in such notice or printed on the Securities.

     At the Company’s request, the Trustee shall give the notice of redemption in the Company’s
name and at the Company’s sole expense.

     3.4. EFFECT OF NOTICE OF REDEMPTION.

     Once the notice of redemption described in Section 3.3 is mailed, Securities of a Series
called for redemption become due and payable on the Redemption Date and at the redemption price,
plus interest, if any, accrued to the Redemption Date. Upon surrender to the Trustee or Paying
Agent, such Securities of a Series shall be paid at the redemption price, plus accrued interest, if
any, to the Redemption Date; PROVIDED, that if the Redemption Date is after a regular interest
payment record date and on or prior to the next Interest Payment Date, the accrued interest shall
be payable to the Holder of the redeemed Securities registered on the relevant record date, as
specified by the Company in the notice to the Trustee pursuant to Section 3.1.

-18-

 

     3.5. DEPOSIT OF REDEMPTION PRICE.

     On or prior to the Redemption Date (but no later than 11:00 A.M. Eastern Time on such date),
the Company shall deposit with the Paying Agent money sufficient to pay the redemption price of and
accrued interest, if any, on all Securities to be redeemed on that date other than Securities or
portions thereof called for redemption on that date which have been delivered by the Company to the
Trustee for cancellation.

     On and after any Redemption Date, if money sufficient to pay the redemption price of, and
accrued interest on, Securities called for redemption shall have been made available in accordance
with the preceding paragraph and the Company and the Paying Agent are not prohibited from paying
such moneys to Holders, the Securities called for redemption will cease to accrue interest and the
only right of the Holders of such Securities will be to receive payment of the redemption price of
and, subject to the proviso in Section 3.4, accrued and unpaid interest on such Securities to the
Redemption Date. If any Security called for redemption shall not be so paid, interest will be paid,
from the Redemption Date until such redemption payment is made, on the unpaid principal of the
Security and any interest or premium, if any, not paid on such unpaid principal, in each case, at
the rate and in the manner provided in the Securities.

     3.6. SECURITIES REDEEMED IN PART.

     Upon surrender of a Security of a Series that is redeemed in part, the Company shall execute,
and the Trustee shall authenticate, for a Holder a new Security of the same Series equal in
principal amount to the unredeemed portion of the Security surrendered.

ARTICLE 4

COVENANTS

     4.1. PAYMENT OF SECURITIES.

     The Company shall pay the principal of, and interest and premium, if any, on, each Series of
Securities on the dates and in the manner provided in such Securities and this Indenture.

     An installment of principal or interest shall be considered paid on the date it is due if the
Trustee or Paying Agent holds on that date money designated for and sufficient to pay such
installment and is not prohibited from paying such money to the Holders pursuant to the terms of
this Indenture or otherwise.

     The Company shall pay interest on overdue principal, and overdue interest, to the extent
lawful, at the rate specified in the Series of Securities.

     4.2. SEC REPORTS.

     The Company will deliver to the Trustee within 15 days after the filing of the same with the
SEC, copies of the quarterly and annual reports and of the information, documents and other
reports, if any, which the Company is required to file with the SEC pursuant to Section 13 or 15(d)
of the Exchange Act; PROVIDED, HOWEVER, that each such report or document will be

-19-

 

deemed to be so delivered to the Trustee if the Company files such report or document with the
SEC through the SEC’s EDGAR database no later than the time such report or document is required to
be filed with the SEC pursuant to the Exchange Act. Notwithstanding that the Company may not be
subject to the reporting requirements of Section 13 or 15(d) of the Exchange Act, the Company will
file with the SEC, to the extent permitted, and provide the Trustee with, such quarterly and annual
reports and such information, documents and other reports specified in Sections 13 and 15(d) of the
Exchange Act. The Company will also comply with the other provisions of TIA Section 314(a).

     4.3. WAIVER OF STAY, EXTENSION OR USURY LAWS.

     The Company covenants (to the extent that it may lawfully do so) that it will not at any time
insist upon, or plead (as a defense or otherwise) or in any manner whatsoever claim or take the
benefit or advantage of, any stay, extension, usury or other law which would prohibit or forgive
the Company from paying all or any portion of the principal of, and/or interest and premium, if
any, on, the Securities as contemplated herein, wherever enacted, now or at any time hereafter in
force, or which may affect the covenants or the performance of this Indenture; and the Company
hereby expressly waives (to the extent that they may lawfully do so) all benefit or advantage of
any such law, and covenants that it will not hinder, delay or impede the execution of any power
herein granted to the Trustee, but will suffer and permit the execution of every such power as
though no such law had been enacted.

     4.4. COMPLIANCE CERTIFICATE.

          (a) The Company shall deliver to the Trustee, within 120 days after the end of each fiscal
year of the Company, an Officers’ Certificate which complies with TIA Section 314(a)(4) stating
that a review of the activities of the Company and its Subsidiaries during such fiscal year has
been made under the supervision of the signing Officers with a view to determining whether the
Company has kept, observed, performed and fulfilled its obligations under this Indenture, and
further stating, as to each such Officer signing such certificate, that to the best of his or her
knowledge the Company has kept, observed, performed and fulfilled each and every covenant contained
in this Indenture and that there is no default in the performance or observance of any of the
terms, provisions and conditions hereof (or, if a Default or Event of Default shall have occurred,
describing all such Defaults or Events of Default of which he or she may have knowledge and what
action the Company is taking or proposes to take with respect thereto) and that to the best of his
or her knowledge no event has occurred and remains in existence by reason of which payments on
account of the principal of, or interest or premium, if any, on, the Securities is prohibited, or
if such event has occurred, a description of the event and what action the Company is taking or
proposes to take with respect thereto.

          (b) (i) If any Default or Event of Default has occurred and is continuing or (ii) if any
Holder seeks to exercise any remedy hereunder with respect to a claimed Default under this
Indenture or the Securities, within five Business Days after the Company becoming aware of such
occurrence the Company shall deliver to the Trustee an Officers’ Certificate specifying such event,
notice or other action and what action the Company is taking or proposes to take with respect
thereto.

-20-

 

     4.5. CORPORATE EXISTENCE.

     Subject to Article 5, the Company shall do or cause to be done all things necessary to
preserve and keep in full force and effect its corporate existence, in accordance with the
organizational documents (as the same may be amended from time to time) of the Company and the
rights (charter and statutory), licenses and franchises of the Company; PROVIDED, HOWEVER, that the
Company shall not be required to preserve any such right, license or franchise, or its corporate
existence, if the Board of Directors shall determine that the preservation thereof is no longer
desirable in the conduct of the business of the Company and that the loss thereof is not adverse in
any material respect to the Holders.

ARTICLE 5

SUCCESSOR CORPORATION

     5.1. LIMITATION ON CONSOLIDATION, MERGER AND SALE OF ASSETS.

          (a) The Company will not, in any transaction or series of transactions, merge or consolidate
with or into, or sell, assign, convey, transfer, lease or otherwise dispose of all or substantially
all of its properties and assets (as an entirety or substantially as an entirety in one transaction
or a series of related transactions), to any Person or Persons, unless at the time of and after
giving effect thereto (i) either (A) if the transaction or series of transactions is a merger or
consolidation, the Company shall be the surviving Person of such merger or consolidation, or (B)
the Person formed by such consolidation or into which the Company is merged or to which the
properties and assets of the Company are transferred (any such surviving Person or transferee
Person being the “Surviving Entity”) shall be a corporation organized and existing under the laws
of the United States of America, any state thereof or the District of Columbia, or a corporation or
comparable legal entity organized under the laws of a foreign jurisdiction and shall expressly
assume by a supplemental indenture executed and delivered to the Trustee, in form reasonably
satisfactory to the Trustee, all of the obligations of the Company (including, without limitation,
the obligation to pay the principal of, and premium and interest, if any, on, the Securities and
the performance of the other covenants) under the Securities of each Series and this Indenture, and
in each case, this Indenture shall remain in full force and effect; and (ii) immediately before and
immediately after giving effect to such transaction or series of transactions on a pro forma basis
(including, without limitation, any Indebtedness incurred or anticipated to be incurred in
connection with or in respect of such transaction or series of transactions), no Default or Event
of Default shall have occurred and be continuing.

          (b) In connection with any consolidation, merger or transfer of assets contemplated by this
Section 5.1, the Company shall deliver, or cause to be delivered, to the Trustee, in form and
substance reasonably satisfactory to the Trustee, an Officers’ Certificate and an Opinion of
Counsel, each stating that such consolidation, merger or transfer, and the supplemental indenture
in respect thereto, comply with this Section 5.1, and that all conditions precedent herein provided
for relating to such transaction or transactions have been complied with.

-21-

 

     5.2. SUCCESSOR PERSON SUBSTITUTED.

     Upon any consolidation, merger or transfer of all or substantially all of the assets of the
Company in accordance with Section 5.1 above, the successor corporation formed by such
consolidation, or into which the Company is merged or to which such transfer is made, shall succeed
to, and be substituted for, and may exercise every right and power of, the Company under this
Indenture with the same effect as if such successor corporation had been named as the Company
herein, and thereafter (except with respect to any such transfer which is a lease) the predecessor
corporation shall be relieved of all obligations and covenants under this Indenture and the
Securities.

ARTICLE 6

DEFAULTS AND REMEDIES

     6.1. EVENTS OF DEFAULT.

     “Events of Default,” wherever used herein with respect to Securities of any Series, means any
one of the following events, unless in the establishing Board Resolution, supplemental indenture or
Officers’ Certificate, it is provided that such Series shall not have the benefit of said Event of
Default:

     (1) there is a default in the payment of any principal of, or premium, if any, on, the
Securities when the same becomes due and payable at Maturity, upon acceleration, redemption
or otherwise;

     (2) there is a default in the payment of any interest on any Security of a Series when
the same becomes due and payable, and the Default continues for a period of 30 days;

     (3) the Company defaults in the observance or performance of any other covenant in the
Securities of a Series or in this Indenture for 60 days after written notice from the
Trustee or the Holders of not less than 25% in the aggregate principal amount of the
Securities of such Series then outstanding, which notice must specify the Default, demand
that it be remedied and state that the notice is a “Notice of Default”;

     (4) the Company or any Significant Subsidiary pursuant to or within the meaning of any
Bankruptcy Law:

     (A) commences a voluntary case,

     (B) consents to the entry of an order for relief against it in an involuntary
case,

     (C) consents to the appointment of a Custodian of it or for all or
substantially all of its property,

     (D) makes a general assignment for the benefit of its creditors, or

-22-

 

     (E) generally is not paying its debts as they become due;

     (5) a court of competent jurisdiction enters an order or decree under any Bankruptcy
Law that:

     (A) is for relief against the Company or any Significant Subsidiary in an
involuntary case;

     (B) appoints a Custodian of the Company or any Significant Subsidiary, or for
all or substantially all of the property of the Company or any Significant
Subsidiary; or

     (C) orders the liquidation of the Company or any Significant Subsidiary, and
the order or decree remains unstayed and in effect for 90 consecutive days; or

     (6) any other Event of Default provided with respect to Securities of that Series,
which is specified in a Board Resolution, a supplemental indenture hereto or an Officers’
Certificate, in accordance with Section 2.2(19).

     The term “Bankruptcy Law” means Title 11, U.S. Code, or any similar federal or state law for
the relief of debtors. The term “Custodian” means any receiver, trustee, assignee, liquidator or
similar official under any Bankruptcy Law.

     The Trustee may withhold notice of any Default (except in the payment of the principal of, or
interest or premium, if any, on, the Securities) to the Holders of the Securities of any Series in
accordance with Section 7.5. When a Default is cured, it ceases to exist.

     6.2. ACCELERATION.

     If an Event of Default with respect to Securities of any Series at the time outstanding (other
than an Event of Default arising under Section 6.1(4) or (5)) occurs and is continuing, the Trustee
by written notice to the Company, or the Holders of not less than 25% in aggregate principal amount
of the Securities of that Series then outstanding by written notice to the Company and the Trustee,
may declare that the entire principal amount of all the Securities of that Series then outstanding
plus accrued and unpaid interest to the date of acceleration are immediately due and payable, in
which case such amounts shall become immediately due and payable; PROVIDED, HOWEVER, that after
such acceleration but before a judgment or decree based on such acceleration is obtained by the
Trustee, the Holders of a majority in aggregate principal amount of the outstanding Securities of
that Series may rescind and annul such acceleration and its consequences if (i) all existing Events
of Default, other than the nonpayment of accelerated principal, interest or premium, if any, that
has become due solely because of the acceleration, have been cured or waived, (ii) to the extent
the payment of such interest is lawful, interest on overdue installments of interest and overdue
principal, which has become due otherwise than by such declaration of acceleration, has been paid
and (iii) the rescission would not conflict with any judgment or decree. No such rescission shall
affect any subsequent Default or impair any right consequent thereto. In case an Event of Default
specified in Section 6.1(4) or (5) with respect to the Company occurs, such principal, premium, if
any, and interest amount

-23-

 

with respect to all of the Securities of that Series shall be due and payable immediately
without any declaration or other act on the part of the Trustee or the Holders of the Securities of
that Series.

     6.3. REMEDIES.

     If an Event of Default with respect to Securities of any Series at the time outstanding occurs
and is continuing, the Trustee may pursue any available remedy by proceeding at law or in equity to
collect the payment of the principal of, or interest and premium, if any, on, the Securities of
that Series, or to enforce the performance of any provision of the Securities of that Series or
this Indenture.

     The Trustee may maintain a proceeding even if it does not possess any of the Securities of
that Series or does not produce any of them in the proceeding. A delay or omission by the Trustee
or any Securityholder in exercising any right or remedy accruing upon an Event of Default shall not
impair the right or remedy or constitute a waiver of or acquiescence in the Event of Default. No
remedy is exclusive of any other remedy. All available remedies are cumulative to the extent
permitted by law.

     6.4. WAIVER OF PAST DEFAULTS AND EVENTS OF DEFAULT.

     Subject to Sections 6.2, 6.7 and 8.2, the Holders of a majority in principal amount of the
Securities of any Series then outstanding have the right to waive any existing Default or Event of
Default with respect to such Series or compliance with any provision of this Indenture (with
respect to such Series) or the Securities of such Series. Upon any such waiver, such Default with
respect to such Series shall cease to exist, and any Event of Default with respect to such Series
arising therefrom shall be deemed to have been cured for every purpose of this Indenture; but no
such waiver shall extend to any subsequent or other Default or Event of Default or impair any right
consequent thereto. This Section 6.4 shall be in lieu of TIA Section 316(a)(1)(B), and TIA Section
316(a)(1)(B) is hereby expressly excluded from this Indenture and Section as permitted by the TIA.

     6.5. CONTROL BY MAJORITY.

     Subject to Sections 6.2, 6.7 and 8.2, the Holders of a majority in principal amount of the
Securities of any Series then outstanding may direct the time, method and place of conducting any
proceeding for any remedy available to the Trustee or exercising any trust or power conferred on
the Trustee by this Indenture with respect to such Series. The Trustee, however, may refuse to
follow any direction that conflicts with law or this Indenture, or that the Trustee determines may
be unduly prejudicial to the rights of another Securityholder, or that may involve the Trustee in
personal liability; PROVIDED, that the Trustee may take any other action deemed proper by the
Trustee which is not inconsistent with such direction. This Section 6.5 shall be in lieu of TIA
Section 316(a)(1)(A), and TIA Section 316(a)(1)(A) is hereby expressly excluded from this Indenture
and Section as permitted by the TIA.

-24-

 

     6.6. LIMITATION ON SUITS.

     Subject to Section 6.7, a Securityholder may not institute any proceeding or pursue any remedy
with respect to this Indenture or the Securities of a Series unless:

     (1) the Holder gives to the Trustee written notice of a continuing Event of Default
with respect to the Securities of that Series;

     (2) the Holders of at least 25% in aggregate principal amount of the Securities of such
Series then outstanding make a written request to the Trustee to pursue the remedy;

     (3) such Holder or Holders offer to the Trustee indemnity reasonably satisfactory to
the Trustee against any loss, liability or expense to be incurred in compliance with such
request;

     (4) the Trustee does not comply with the request within 60 days after receipt of the
request and the offer of indemnity; and

     (5) no direction inconsistent with such written request has been given to the Trustee
during such 60-day period by the Holders of a majority in aggregate principal amount of the
Securities of such Series then outstanding.

     A Securityholder may not use this Indenture to prejudice the rights of another Securityholder,
or to obtain a preference or priority over another Securityholder.

     6.7. RIGHTS OF HOLDERS TO RECEIVE PAYMENT.

     Notwithstanding any other provision of this Indenture, the right of any Holder of a Security
of a Series to receive payment of the principal of, and interest and premium, if any, on, the
Security of such Series on or after the respective due dates expressed in the Security of such
Series, or to bring suit for the enforcement of any such payment on or after such respective dates,
is absolute and unconditional, and shall not be impaired or affected without the consent of the
Holder.

     6.8. COLLECTION SUIT BY TRUSTEE.

     If an Event of Default in payment of principal, interest or premium, if any, specified in
Section 6.1(1) or (2) with respect to Securities of any Series at the time outstanding occurs and
is continuing, the Trustee may recover judgment in its own name and as trustee of an express trust
against the Company (or any other obligor on the Securities of that Series) for the whole amount of
unpaid principal and premium, if any, and accrued interest remaining unpaid, together with interest
on overdue principal and premium, if any, and, to the extent that payment of such interest is
lawful, interest on overdue installments of interest, in each case at the rate then borne by the
Securities of that Series, and such further amounts as shall be sufficient to cover the costs and
expenses of collection, including the reasonable compensation, expenses, disbursements and advances
of the Trustee, its agents and counsel, as set forth in Section 7.7.

-25-

 

     6.9. TRUSTEE MAY FILE PROOFS OF CLAIM.

     The Trustee may file such proofs of claim and other papers or documents, and take other
actions (including sitting on a committee of creditors), as may be necessary or advisable in order
to have the claims of the Trustee (including any claim for the reasonable compensation, expenses,
disbursements and advances of the Trustee, its agents and counsel) and the Securityholders allowed
in any judicial proceedings relative to the Company (or any other obligor on the Securities), any
of their respective creditors or any of their respective property, and the Trustee shall be
entitled and empowered to collect and receive any monies or other property payable or deliverable
on any such claims, and to distribute the same after deduction of its charges and expenses to the
extent that any such charges and expenses are not paid out of the estate in any such proceedings,
and any custodian in any such judicial proceeding is hereby authorized by each Securityholder to
make such payments to the Trustee, and in the event that the Trustee shall consent to the making of
such payments directly to the Securityholders, to pay to the Trustee any amount due to it for the
reasonable compensation, expenses, disbursements and advances of the Trustee, its agents and
counsel, and any other amounts due the Trustee under Section 7.7.

     Nothing herein contained shall be deemed to authorize the Trustee to authorize or consent to,
or accept or adopt on behalf of any Securityholder, any plan of reorganization, arrangement,
adjustment or composition affecting the Securities of a Series or the rights of any Holder thereof,
or to authorize the Trustee to vote in respect of the claim of any Securityholder in any such
proceedings.

     6.10. PRIORITIES.

     If the Trustee collects any money pursuant to this Article 6, it shall pay out the money in
the following order:

     FIRST: to the Trustee for amounts due under Section 7.7;

SECOND: to Securityholders for amounts then due and unpaid for the principal of, and
interest and premium, if any, on, the Securities in respect of which, or for the benefit of
which, such money has been collected, ratably, without preference or priority of any kind,
according to the amounts due and payable on such Securities; for principal and any premium
and interest, respectively; and

     THIRD: to the Company.

     The Trustee may fix a record date and payment date for any payment to Securityholders pursuant
to this Section 6.10. At least 15 days before such record date, the Trustee shall mail to each
Securityholder a notice that states the record date, the payment date and amount to be paid.

     6.11. UNDERTAKING FOR COSTS.

     In any suit for the enforcement of any right or remedy under this Indenture, or in any suit
against the Trustee for any action taken or omitted by it as Trustee, a court in its discretion may
require the filing by any party litigant in the suit of an undertaking to pay the costs of the
suit,

-26-

 

and the court in its discretion may assess reasonable costs, including reasonable attorneys’
fees, against any party litigant in the suit, having due regard to the merits and good faith of the
claims or defenses made by the party litigant. This Section 6.11 does not apply to a suit by the
Trustee, a suit by a Holder pursuant to Section 6.7 or a suit by Holders of more than 10% in
principal amount of the Securities of a Series then outstanding.

ARTICLE 7

TRUSTEE

     7.1. DUTIES OF TRUSTEE.

          (a) If an Event of Default has occurred and is continuing, the Trustee shall exercise such of
the rights and powers vested in it by this Indenture and use the same degree of care and skill in
their exercise as a prudent Person would exercise or use under the same circumstances in the
conduct of his own affairs.

          (b) Except during the continuance of an Event of Default:

     (1) The Trustee need perform only those duties that are specifically set forth
in this Indenture, and no covenants or obligations shall be implied in this
Indenture against the Trustee.

     (2) In the absence of bad faith on its part, the Trustee may conclusively rely,
as to the truth of the statements and the correctness of the opinions expressed
therein, upon certificates or opinions furnished to the Trustee and conforming to
the requirements of this Indenture, but, in the case of any such certificates or
opinions which by any provision hereof are specifically required to be furnished to
the Trustee, the Trustee shall be under a duty to examine the same to determine
whether or not they conform to the requirements of this Indenture.

          (c) The Trustee may not be relieved from liability for its own negligent action, its own
negligent failure to act or its own willful misconduct, except that:

     (1) This paragraph does not limit the effect of paragraph (b) of this Section
7.1.

     (2) The Trustee shall not be liable for any error of judgment made in good
faith by a Responsible Officer, unless it is proved that the Trustee was negligent
in ascertaining the pertinent facts.

     (3) The Trustee shall not be liable with respect to any action it takes or
omits to take in good faith in accordance with a direction received by it pursuant
to Sections 6.2 and 6.5.

          (d) No provision of this Indenture shall require the Trustee to expend or risk its own funds,
or otherwise incur any financial liability, in the performance of any of its rights or

-27-

 

powers if it
shall have reasonable grounds for believing that repayment of such funds or adequate indemnity
satisfactory to it against such risk or liability is not reasonably assured to it.

          (e) Whether or not therein expressly so provided, paragraphs (a), (b), (c) and (d) of this
Section 7.1 shall govern every provision of this Indenture that in any way relates to the Trustee.

          (f) The Trustee and Paying Agent shall not be liable for interest on any money received by
either of them, except as the Trustee and Paying Agent may agree in writing with the Company. Money
held in trust by the Trustee need not be segregated from other funds except to the extent required
by the law.

          (g) The Paying Agent, the Registrar and any authenticating agent shall be entitled to the
protections, immunities and standard of care set forth in paragraphs (a), (b), (c), (d) and (f) of
this Section 7.1 and in Section 7.2 with respect to the Trustee.

     7.2. RIGHTS OF TRUSTEE.

          (a) Subject to Section 7.1:

     (1) The Trustee may rely on, and shall be protected in acting or refraining
from acting upon, any document reasonably believed by it to be genuine and to have
been signed or presented by the proper Person. The Trustee need not investigate any
fact or matter stated in the document.

     (2) Before the Trustee acts or refrains from acting, it may require an
Officers’ Certificate or an Opinion of Counsel, or both, which shall conform to the
provisions of Section 10.5. The Trustee shall be protected and shall not be liable
for any action it takes or omits to take in good faith in reliance on such
certificate or opinion.

     (3) The Trustee may act through agents and attorneys, and shall not be
responsible for the misconduct or negligence of any agent appointed by it with due
care.

     (4) The Trustee shall not be liable for any action it takes or omits to take in
good faith which it reasonably believes to be authorized or within its rights or
powers.

     (5) The Trustee may consult with counsel reasonably acceptable to the Trustee,
which may be counsel to the Company, and the advice or opinion of such counsel as to
matters of law shall be full and complete authorization and protection from
liability in respect of any action taken, omitted or suffered by it hereunder in
good faith and in accordance with the advice or opinion of such counsel.

     (6) The Trustee shall be under no obligation to exercise any of the rights or
powers vested in it by this Indenture at the request, order or direction of

-28-

 

any of
the Holders pursuant to the provisions of this Indenture, unless such Holders shall
have offered to the Trustee reasonable security or indemnity against the costs,
expenses and liabilities which may be incurred therein or thereby.

     (7) The Trustee shall not be deemed to have knowledge of any fact or matter
(including, without limitation, a Default or Event of Default) unless such fact or
matter is known to a Responsible Officer of the Trustee.

     (8) Unless otherwise expressly provided herein or in the Securities of a Series
or the related Board Resolution, supplemental indenture or Officers’ Certificate,
the Trustee shall not have any responsibility with respect to reports, notices,
certificates or other documents filed with it hereunder, except to make them
available for inspection, at reasonable times, by Securityholders, it being
understood that delivery of such reports, information and documents to the Trustee
is for informational purposes only and the Trustee’s receipt of such shall not
constitute constructive notice of any information contained therein or determinable
from information contained therein, including the Company’s compliance with any of
its covenants hereunder (except as set forth in Section 4.4).

     7.3. INDIVIDUAL RIGHTS OF TRUSTEE.

     The Trustee in its individual or any other capacity may become the owner or pledgee of
Securities, and may make loans to, accept deposits from, perform services for or otherwise deal
with the Company, or any Affiliate thereof, with the same rights it would have if it were not
Trustee. Any Agent may do the same with like rights. The Trustee, however, shall be subject to
Sections 7.10 and 7.11.

     7.4. TRUSTEE’S DISCLAIMER.

     The Trustee makes no representation as to the validity or adequacy of this Indenture or the
Securities (except that the Trustee represents that it is duly authorized to execute and deliver
this Indenture and authenticate the Securities and perform its obligations hereunder), and the
Trustee shall not be accountable for the Company’s use of the proceeds from the sale of Securities
or any money paid to the Company pursuant to the terms of this Indenture, and the Trustee shall not
be responsible for any statement in the Securities other than its certificates of authentication.

     7.5. NOTICE OF DEFAULT.

     If a Default or an Event of Default occurs and is continuing with respect to the Securities of
any Series, and if it is known to the Trustee, the Trustee shall mail to each Securityholder of the
Securities of that Series notice of the Default or the Event of Default, as the case may be, within
90 days after it occurs or, if later, after a Responsible Officer of the Trustee has knowledge of
such Default or Event of Default (except if such Default or Event of Default has been validly cured
or waived before the giving of such notice). Except in the case of a Default or an Event of Default
in payment of the principal of, or interest or premium, if any, on, any Security of any Series, the
Trustee may withhold the notice if and so long as the Board of

-29-

 

Directors of the Trustee, the
executive committee or any trust committee of such board and/or its Responsible Officers in good
faith determine(s) that withholding the notice is in the interests of the Securityholders of that
Series.

     7.6. REPORTS BY TRUSTEE TO HOLDERS.

     If and to the extent required by the TIA, within 60 days after April 1 of each year,
commencing the April 1 following the date of this Indenture, the Trustee shall mail to each
Securityholder a brief report dated as of such April 1 that complies with TIA Section 313(a). The
Trustee also shall comply with TIA Sections 313(b) and 313(c).

     A copy of each report at the time of its mailing to Securityholders shall be filed with the
SEC and any stock exchange on which the Securities of that Series are listed. The Company shall
promptly notify the Trustee when the Securities of any Series are listed on any stock exchange or
any delisting thereof, and the Trustee shall comply with TIA Section 313(d).

     7.7. COMPENSATION AND INDEMNITY.

     The Company shall pay to the Trustee from time to time reasonable compensation for its
services. The Trustee’s compensation shall not be limited by any provision of law on compensation
of a trustee of an express trust. The Company shall reimburse the Trustee within 45 days after
receipt of request for all reasonable out-of-pocket disbursements and expenses incurred or made by
it in connection with its duties under this Indenture, including the reasonable compensation,
disbursements and expenses of the Trustee’s agents and counsel.

     The Company shall indemnify the Trustee for, and hold it harmless against, any and all loss or
liability incurred by it in connection with the acceptance or performance of its duties under this
Indenture including the reasonable costs and expenses of defending itself against any claim or
liability in connection with the exercise or performance of any of its powers or duties hereunder.
The Trustee shall notify the Company promptly of any claim asserted against the Trustee for which
it may seek indemnity.

     The failure by the Trustee to so notify the Company shall not however relieve the Company of
its obligations. Notwithstanding the foregoing, the Company need not reimburse the Trustee for any
expense or indemnify it against any loss or liability incurred by the Trustee through its
negligence or bad faith. To secure the payment obligations of the Company in this Section 7.7, the
Trustee shall have a lien prior to the Securities of any Series on all money or property held or
collected by the Trustee except such money or property held in trust to pay the principal of,
interest and premium, if any, on particular Securities of that Series.

     When the Trustee incurs expenses or renders services after an Event of Default specified in
Section 6.1(4) or (5) occurs, the expenses and the compensation for the services are intended to
constitute expenses of administration under any Bankruptcy Law.

     For purposes of this Section 7.7, the term “Trustee” shall include any trustee appointed
pursuant to this Article 7.

-30-

 

     7.8. REPLACEMENT OF TRUSTEE.

     The Trustee may resign with respect to the Securities of one or more Series by so notifying
the Company in writing at least 90 days in advance of such resignation.

     The Holders of a majority in principal amount of the outstanding Securities of any Series may
remove the Trustee with respect to that Series by notifying the removed Trustee in writing and may
appoint a successor Trustee with respect to that Series with the consent of the Company, which
consent shall not be unreasonably withheld. The Company may remove the Trustee with respect to that
Series at its election if:

     (1) the Trustee fails to comply with, or ceases to be eligible under, Section 7.10;

     (2) the Trustee is adjudged a bankrupt or an insolvent, or an order for relief is
entered with respect to the Trustee, under any Bankruptcy Law;

     (3) a Custodian or other public officer takes charge of the Trustee or its property; or

     (4) the Trustee otherwise becomes incapable of acting.

     (5) If the Trustee resigns or is removed, or if a vacancy exists in the office of
Trustee, with respect to any Series of Securities for any reason, the Company shall promptly
appoint, by Board Resolution, a successor Trustee.

     If a successor Trustee with respect to the Securities of one or more Series does not take
office within 60 days after the retiring Trustee resigns or is removed, the retiring Trustee, the
Company or the Holders of at least 10% in principal amount of the outstanding Securities of the
applicable Series may petition any court of competent jurisdiction for the appointment of a
successor Trustee.

     If the Trustee with respect to the Securities of one or more Series fails to comply with
Section 7.10, any Securityholder of the applicable Series may petition any court of competent
jurisdiction for the removal of the Trustee and the appointment of a successor Trustee.

     A successor Trustee shall deliver a written acceptance of its appointment to the retiring
Trustee and to the Company. Immediately following such delivery, (i) the retiring Trustee with
respect to one or more Series shall, subject to its rights under Section 7.7, transfer all property
held by it as Trustee with respect to such Series to the successor Trustee, (ii) the resignation or
removal of the retiring Trustee shall become effective and (iii) the successor Trustee with respect
to such Series shall have all the rights, powers and duties of the Trustee under this Indenture. A
successor Trustee with respect to the Securities of one or more Series shall mail notice of its
succession to each Securityholder of such Series.

-31-

 

     7.9. SUCCESSOR TRUSTEE BY CONSOLIDATION, MERGER OR CONVERSION.

     If the Trustee, or any Agent, consolidates with, merges or converts into, or transfers all or
substantially all of its corporate trust assets to, another corporation, subject to Section 7.10,
the successor corporation without any further act shall be the successor Trustee or Agent, as the
case may be.

     7.10. ELIGIBILITY; DISQUALIFICATION.

     This Indenture shall always have a Trustee who satisfies the requirements of TIA Sections
310(a)(1), (2) and (5) in every respect. The Trustee (or in the case of a Trustee that is a Person
included in a bank holding company system, the related bank holding company) shall have a combined
capital and surplus of at least $100,000,000 as set forth in its most recent published annual
report of condition. The Trustee shall comply with TIA Section 310(b), including the provision in
Section 310(b)(1). In addition, if the Trustee is a Person included in a bank holding company
system, the Trustee, independently of such bank holding company, shall meet the capital
requirements of TIA Section 310(a)(2). If at any time the Trustee shall cease to be eligible in
accordance with the provisions of this Section 7.10, it shall resign immediately in the manner and
with the effect specified in this Article 7.

     7.11. PREFERENTIAL COLLECTION OF CLAIMS AGAINST COMPANY.

     The Trustee shall comply with TIA Section 311(a), excluding any creditor relationship listed
in TIA Section 311(b). A Trustee who has resigned or been removed shall be subject to TIA Section
311(a) to the extent indicated therein.

     7.12. PAYING AGENTS.

     The Company shall cause each Paying Agent other than the Trustee to execute and deliver to it
and the Trustee an instrument in which such agent shall agree with the Trustee, subject to the
provisions of this Section 7.12:

     (1) that it will hold all sums held by it as agent for the payment of the principal of,
or interest or premium, if any, on, the Securities (whether such sums have been paid to it
by the Company or by any obligor on the Securities) in trust for the benefit of Holders of
the Securities or the Trustee;

     (2) that it will at any time during the continuance of any Event of Default, upon
written request from the Trustee, deliver to the Trustee all sums so held in trust by it
together with a full accounting thereof; and

     (3) that it will give the Trustee written notice within three Business Days after any
failure of the Company (or by any obligor on the Securities) in the payment of any
installment of the principal of, or interest or premium, if any, on, the Securities when the
same shall be due and payable.

-32-

 

ARTICLE 8

AMENDMENTS, SUPPLEMENTS AND WAIVERS

     8.1. WITHOUT CONSENT OF HOLDERS.

     The Company, when authorized by a Board Resolution, and the Trustee may amend or supplement
this Indenture or the Securities of one or more Series without notice to or consent of any
Securityholder:

     (1) to comply with Section 5.1;

     (2) to provide for certificated Securities in addition to uncertificated Securities;

     (3) to comply with any requirements of the SEC under the TIA;

     (4) to cure any ambiguity, defect or inconsistency, or to make any other change herein
or in the Securities that does not materially and adversely affect the rights of any
Securityholder;

     (5) to provide for the issuance of, and establish the form and terms and conditions of,
Securities of any Series as permitted by this Indenture; or

     (6) to evidence and provide for the acceptance of appointment hereunder by a successor
Trustee with respect to the Securities of one or more Series, and to add to or change any of
the provisions of this Indenture as shall be necessary to provide for or facilitate the
administration of the trusts hereunder by more than one Trustee.

     The Trustee is hereby authorized to join with the Company in the execution of any supplemental
indenture authorized or permitted by the terms of this Indenture, and to make any further
appropriate agreements and stipulations which may be therein contained, but the Trustee shall not
be obligated to enter into any such supplemental indenture which adversely affects its own rights,
duties or immunities under this Indenture.

     8.2. WITH CONSENT OF HOLDERS.

          (a) The Company, when authorized by a Board Resolution, and the Trustee may amend or
supplement this Indenture or the Securities of one or more Series with the written consent of the
Holders of not less than a majority in aggregate principal amount of the outstanding Securities of
such Series affected by such amendment or supplement without notice to any Securityholder. The
Holders of not less than a majority in aggregate principal amount of the outstanding Securities of
each such Series affected by such amendment or supplement may waive compliance by the Company in a
particular instance with any provision of this Indenture or the Securities of such Series without
notice to any Securityholder. Subject to Section 8.4, without the consent of each Securityholder
affected, however, an amendment, supplement or waiver may not:

-33-

 

     (1) reduce the amount of Securities whose Holders must consent to an amendment,
supplement or waiver to this Indenture or the Securities;

     (2) reduce the rate of, or change the time for payment of, interest on any
Security;

     (3) reduce the principal, or change the Stated Maturity, of any Security, or
reduce the amount of, or postpone the date fixed for, the payment of any sinking
fund or analogous obligation;

     (4) make any Security payable in money other than that stated in the Security;

     (5) change the amount or time of any payment required by the Securities, or
reduce the premium payable upon any redemption of the Securities, or change the time
before which no such redemption may be made;

     (6) waive a Default or Event of Default in the payment of the principal of, or
interest or premium, if any, on, any Security (except a rescission of acceleration
of the Securities of any Series by the Holders of at least a majority in principal
amount of the outstanding Securities of such Series and a waiver of the payment
default that resulted from such acceleration);

     (7) waive a redemption payment with respect to any Security, or change any of
the provisions with respect to the redemption of any Securities;

     (8) make any changes in Section 6.6 or this Section 8.2, except to increase any
percentage of Securities the Holders of which must consent to any matter; or

     (9) take any other action otherwise prohibited by this Indenture to be taken
without the consent of each Holder affected thereby.

          (b) Upon the request of the Company, accompanied by a Board Resolution authorizing the
execution of any such supplemental indenture, and upon the receipt by the Trustee of evidence
reasonably satisfactory to the Trustee of the consent of the Securityholders as aforesaid and of
the documents described in Section 8.6, the Trustee shall join with the Company in the execution of
such supplemental indenture, unless such supplemental indenture affects the Trustee’s own rights,
duties or immunities under this Indenture, in which case the Trustee may in its discretion, but
shall not be obligated to, enter into such supplemental indenture.

          (c) It shall not be necessary for the consent of the Holders under this section to approve the
particular form of any proposed amendment, supplement or waiver, but it shall be sufficient if such
consent approves the substance thereof.

     After an amendment or supplement under this Section becomes effective, the Company shall mail
to Securityholders a notice briefly describing the amendment or supplement. Any

-34-

 

failure of the Company to mail any such notice, or any defect therein, shall not, however, in any way impair or
affect the validity of any supplemental indenture.

     8.3. COMPLIANCE WITH TRUST INDENTURE ACT.

     Every amendment to, or supplement of, this Indenture or the Securities shall comply with the
TIA as then in effect.

     8.4. REVOCATION AND EFFECT OF CONSENTS.

     Until an amendment, supplement, waiver or other action becomes effective, a consent to it by a
Holder of a Security is a continuing consent conclusive and binding upon such Holder and every
subsequent Holder of the same Security or portion thereof, and of any Security issued upon the
transfer thereof or in exchange therefor or in place thereof, even if notation of the consent is
not made on any such Security. Any such Holder or subsequent Holder, however, may revoke the
consent as to his Security or portion of a Security, if the Trustee receives the notice of
revocation before the date the amendment, supplement, waiver or other action becomes effective.

     The Company may, but shall not be obligated to, fix a record date for the purpose of
determining the Holders entitled to consent to any amendment, supplement or waiver, which record
date shall be at least 30 days prior to the first solicitation of such consent. If a record date is
fixed, then, notwithstanding the preceding paragraph, those Persons who were Holders at such record
date (or their duly designated proxies), and only such Persons, shall be entitled to consent to
such amendment, supplement or waiver, or to revoke any consent previously given, whether or not
such Persons continue to be Holders after such record date.

     After an amendment, supplement, waiver or other action becomes effective, it shall bind every
Securityholder, unless it makes a change described in any of clauses (1) through (9) of Section
8.2. In that case, the amendment, supplement, waiver or other action shall bind each Holder of a
Security who has consented to it and every subsequent Holder of a Security or portion of a Security
that evidences the same debt as the consenting Holder’s Security; PROVIDED, that any such waiver
shall not impair or affect the right of any Holder to receive payment of the principal of, and
interest and premium, if any, on, a Security, on or after the respective due dates expressed in
such Security, or to bring suit for the enforcement of any such payment on or after such respective
dates without the consent of such Holder.

     8.5. NOTATION ON OR EXCHANGE OF SECURITIES.

     If an amendment, supplement or waiver changes the terms of a Security of any Series, the
Trustee may request the Holder of such Security to deliver it to the Trustee. In such case, the
Trustee shall place an appropriate notation on such Security about the changed terms and return it
to the Holder. Alternatively, the Company, in exchange for such Security, may issue, and the
Trustee shall authenticate, a new security that reflects the changed terms. Failure to make the
appropriate notation or issue a new Security shall not affect the validity and effect of such
amendment, supplement or waiver.

-35-

 

     8.6. TRUSTEE TO SIGN AMENDMENTS, ETC.

     The Trustee shall sign any amendment, supplement or waiver authorized pursuant to this Article
8 if the amendment, supplement or waiver does not adversely affect the rights, duties, liabilities
or immunities of the Trustee. If it does, the Trustee may, but need not, sign it. In signing or
refusing to sign such amendment, supplement or waiver the Trustee shall be entitled to receive and,
subject to Section 7.1, shall be fully protected in relying upon an Officers’ Certificate and an
Opinion of Counsel stating that such amendment, supplement or waiver is authorized or permitted by
this Indenture. The Company may not sign an amendment or supplement until the Board of Directors of
the Company approves it.

ARTICLE 9

DISCHARGE OF INDENTURE; DEFEASANCE

     9.1. DISCHARGE OF INDENTURE.

     The Company may terminate its obligations under the Securities of any Series and this
Indenture with respect to such Series, except the obligations referred to in the last paragraph of
this Section 9.1, if there shall have been canceled by the Trustee, or delivered to the Trustee for
cancellation, all Securities of such Series theretofore authenticated and delivered (other than
any Securities of such Series that are asserted to have been destroyed, lost or stolen and that
shall have been replaced as provided in Section 2.8) and the Company has paid all sums payable by
it hereunder or deposited all required sums with the Trustee.

     After such delivery the Trustee upon request shall acknowledge in a writing prepared by or on
behalf of the Company the discharge of the Company’s obligations under the Securities of such
Series and this Indenture, except for those surviving obligations specified below.

     Notwithstanding the satisfaction and discharge of this Indenture, the obligations of the
Company in Sections 7.7, 9.5 and 9.6 shall survive.

     9.2. LEGAL DEFEASANCE.

     The Company may at its option, by Board Resolution, be discharged from its obligations with
respect to the Securities of any Series on the date upon which the conditions set forth in Section
9.4 below are satisfied (hereinafter, “Legal Defeasance”). For this purpose, such Legal Defeasance
means that the Company shall be deemed to have paid and discharged the entire indebtedness
represented by the Securities of such Series and to have satisfied all its other obligations under
such Securities and this Indenture insofar as such Securities are concerned (and the Trustee, at
the expense of the Company, shall, subject to Section 9.6, execute proper instruments acknowledging
the same, as are delivered to it by the Company), except for the following, which shall survive
until otherwise terminated or discharged hereunder: (A) the rights of Holders of outstanding
Securities of such Series to receive solely from the trust funds described in Section 9.4 and as
more fully set forth in such section, payments in respect of the principal of, and interest and
premium, if any, on, the Securities of such Series when such payments are due, (B) the Company’s
obligations with respect to the Securities of such Series under Sections 2.4, 2.5, 2.6, 2.7, 2.8
and 2.9, (C) the rights, powers, trusts, duties and immunities

-36-

 

of the Trustee hereunder (including claims of, or payments to, the Trustee under or pursuant to Section 7.7) and (D) this Article 9.
Subject to compliance with this Article 9, the Company may exercise its option under this Section
9.2 with respect to the Securities of any Series notwithstanding the prior exercise of its option
under Section 9.3 below with respect to the Securities of such Series.

     9.3. COVENANT DEFEASANCE.

     At the option of the Company, pursuant to a Board Resolution, the Company shall be released
from its obligations with respect to the outstanding Securities of any Series under Sections 4.2
through 4.5, inclusive, and Section 5.1, with respect to the outstanding Securities of such Series,
on and after the date the conditions set forth in Section 9.4 are satisfied (hereinafter, “Covenant
Defeasance”). For this purpose, such Covenant Defeasance means that the Company may omit to comply
with and shall have no liability in respect of any term, condition or limitation set forth in any
such specified section or portion thereof, whether directly or indirectly by reason of any
reference elsewhere herein to any such specified Section or portion thereof or by reason of any
reference in any such specified section or portion thereof to any other provision herein or in any
other document, but the remainder of this Indenture and the Securities of any Series shall be
unaffected thereby.

     9.4. CONDITIONS TO LEGAL DEFEASANCE OR COVENANT DEFEASANCE.

     The following shall be the conditions to application of Section 9.2 or Section 9.3 to the
outstanding Securities of a Series:

     (1) the Company shall irrevocably have deposited or caused to be deposited with the
Trustee (or another trustee satisfying the requirements of Section 7.10 who shall agree to
comply with the provisions of this Article 9 applicable to it) as funds in trust for the
purpose of making the following payments, specifically pledged as security for, and
dedicated solely to, the benefit of the Holders of the Securities, (A) money in an amount,
or (B) U.S. Government Obligations or Foreign Government Obligations which through the
scheduled payment of principal and interest in respect thereof in accordance with their
terms will provide, not later than the due date of any payment, money in an amount, or (C) a
combination thereof, sufficient, in the opinion of a nationally recognized firm of
independent public accountants expressed in a written certification thereof delivered to the
Trustee, to pay and discharge, and which shall be applied by the Trustee (or other
qualifying trustee) to pay and discharge, the principal of, and accrued interest and
premium, if any, on, the outstanding Securities of such Series at the Stated Maturity of
such principal, interest or premium, if any, or on dates for payment and redemption of such
principal, interest and premium, if any, selected in accordance with the terms of this
Indenture and of the Securities of such Series;

     (2) no Event of Default or Default with respect to the Securities of such Series shall
have occurred and be continuing on the date of such deposit, or shall have occurred and be
continuing at any time during the period ending on the 91st day after the date of such
deposit or, if longer, ending on the day following the expiration of the longest

-37-

 

preference period under any Bankruptcy Law applicable to the Company in respect of such deposit as
specified in the Opinion of Counsel identified in paragraph (8) below (it being understood
that this condition shall not be deemed satisfied until the expiration of such period);

     (3) such Legal Defeasance or Covenant Defeasance shall not cause the Trustee to have a
conflicting interest for purposes of the TIA with respect to any securities of the Company;

     (4) such Legal Defeasance or Covenant Defeasance shall not result in a breach or
violation of, or constitute default under, any other agreement or instrument to which the
Company is a party or by which it is bound;

     (5) the Company shall have delivered to the Trustee an Opinion of Counsel stating that,
as a result of such Legal Defeasance or Covenant Defeasance, neither the trust nor the
Trustee will be required to register as an investment company under the Investment Company
Act of 1940, as amended;

     (6) in the case of an election under Section 9.2, the Company shall have delivered to
the Trustee an Opinion of Counsel stating that (i) the Company has received from, or there
has been published by, the Internal Revenue Service a ruling to the effect that or (ii)
there has been a change in any applicable Federal income tax law with the effect that, and
such opinion shall confirm that, the Holders of the outstanding Securities of such Series or
Persons in their positions will not recognize income, gain or loss for Federal income tax
purposes solely as a result of such Legal Defeasance and will be subject to Federal income
tax on the same amounts, in the same manner, including as a result of prepayment, and at the
same times as would have been the case if such Legal Defeasance had not occurred;

     (7) in the case of an election under Section 9.3, the Company shall have delivered to
the Trustee an Opinion of Counsel to the effect that the Holders of the outstanding
Securities of such Series will not recognize income, gain or loss for Federal income tax
purposes as a result of such Covenant Defeasance, and will be subject to Federal income tax
on the same amounts, in the same manner and at the same times as would have been the case if
such Covenant Defeasance had not occurred;

     (8) the Company shall have delivered to the Trustee an Officers’ Certificate and an
Opinion of Counsel, each stating that all conditions precedent provided for in this Article
9 relating to either the Legal Defeasance under Section 9.2 or the Covenant Defeasance under
Section 9.3 (as the case may be) have been complied with;

     (9) the Company shall have delivered to the Trustee an Officers’ Certificate stating
that the deposit under clause (1) was not made by the Company with the intent of defeating,
hindering, delaying or defrauding any creditors of the Company or others; and

     (10) the Company shall have paid, or duly provided for payment under terms mutually
satisfactory to the Company and the Trustee, all amounts then due to the Trustee pursuant to
Section 7.7.

-38-

 

     9.5. DEPOSITED MONEY AND U.S. AND FOREIGN GOVERNMENT OBLIGATIONS TO BE HELD IN TRUST; OTHER
MISCELLANEOUS PROVISIONS.

     All money, U.S. Government Obligations and Foreign Government Obligations (including the
proceeds thereof) deposited with the Trustee pursuant to Section 9.4 in respect of the outstanding
Securities shall be held in trust and applied by the Trustee, in accordance with the provisions of
such Securities and this Indenture, to the payment, either directly or through any Paying Agent as
the Trustee may determine, to the Holders of such Securities, of all sums due and to become due
thereon in respect of principal, accrued interest and premium, if any, but such money need not be
segregated from other funds except to the extent required by law.

     The Company shall pay and indemnify the Trustee against any tax, fee or other charge imposed
on or assessed against the U.S. Government Obligations and Foreign Government Obligations deposited
pursuant to Section 9.4 or the principal, interest and premium, if any, received in respect thereof
other than any such tax, fee or other charge which by law is for the account of the Holders of the
outstanding Securities.

     Anything in this Article 9 to the contrary notwithstanding, but subject to payment of any of
its outstanding fees and expenses, the Trustee shall deliver or pay to the Company from time to
time upon Company Request any money, U.S. Government Obligations or Foreign Government Obligations
held by the Trustee as provided in Section 9.4 which, in the opinion of a nationally-recognized
firm of independent public accountants expressed in a written certification thereof delivered to
the Trustee, are in excess of the amount thereof which would then be required to be deposited to
effect an equivalent Legal Defeasance or Covenant Defeasance.

     9.6. REINSTATEMENT.

     If the Trustee or Paying Agent is unable to apply any money, U.S. Government Obligations or
Foreign Government Obligations in accordance with Section 9.1, 9.2, 9.3 or 9.4 by reason of any
legal proceeding or by reason of any order or judgment of any court or governmental authority
enjoining, restraining or otherwise prohibiting such application, the Company’s obligations under
this Indenture and the Securities shall be revived and reinstated as though no deposit had occurred
pursuant to this Article 9 until such time as the Trustee or Paying Agent is permitted to apply all
such money, U.S. Government Obligations or Foreign Government Obligations, as the case may be, in
accordance with Section 9.1, 9.2, 9.3 or 9.4; PROVIDED, HOWEVER, that if the Company has made any
payment of principal of, or accrued interest or premium, if any, on, any Securities because of the
reinstatement of its obligations, the Company shall be subrogated to the rights of the Holders of
such Securities to receive such payment from the money, U.S. Government Obligations or Foreign
Government Obligations held by the Trustee or Paying Agent.

     9.7. MONEYS HELD BY PAYING AGENT.

     In connection with the satisfaction and discharge of this Indenture, all moneys then held by
any Paying Agent under the provisions of this Indenture shall, upon demand of the Company, be paid
to the Trustee, or, if sufficient moneys have been deposited pursuant to Section 9.1, to

-39-

 

the Company, and thereupon such Paying Agent shall be released from all further liability with respect
to such moneys.

     9.8. MONEYS HELD BY TRUSTEE.

     Any moneys deposited with the Trustee or any Paying Agent or then held by the Company in trust
for the payment of the principal of, or interest or premium, if any, on, any Security that are not
applied but remain unclaimed by the Holder of such Security for two years after the date upon which
the principal of, or interest or premium, if any, on, such Security shall have respectively become
due and payable shall be repaid to the Company upon Company Request, or if such moneys are then
held by the Company in trust, such moneys shall be released from such trust; and the Holder of such
Security entitled to receive such payment shall thereafter, as an unsecured general creditor, look
only to the Company for the payment thereof, and all liability of the Trustee or such Paying Agent
with respect to such trust money shall thereupon cease; PROVIDED, HOWEVER, that the Trustee or any
such Paying Agent, before being required to make any such repayment, may, at the expense of the
Company, either mail to each Securityholder affected, at the address shown in the register of the
Securities maintained by the Registrar, or cause to be published once a week for two successive
weeks, in a newspaper published in the English language, customarily published each Business Day
and of general circulation in the City of New York, New York, a notice that such money remains
unclaimed and that, after a date specified therein, which shall not be less than 30 days from the
date of such mailing or publication, any unclaimed balance of such moneys then remaining will be
repaid to the Company. After payment to the Company or the release of any money held in trust by
the Company, Securityholders entitled to the money must look only to the Company for payment as
general creditors, unless applicable abandoned property law designates another Person.

ARTICLE 10

MISCELLANEOUS

     10.1. TRUST INDENTURE ACT CONTROLS.

     If any provision of this Indenture limits, qualifies or conflicts with another provision which
is required to be included in this Indenture by the TIA, the required provision shall control. If
any provision of this Indenture modifies or excludes any provision of the TIA which may be so
modified or excluded, the latter provision shall be deemed to apply to this Indenture as so
modified or to be excluded, as the case may be.

     10.2. NOTICES.

     Any notice or communication shall be given in writing and delivered in Person, sent by
facsimile (and receipt confirmed by telephone or electronic transmission report), delivered by
commercial courier service or mailed by first-class mail, postage prepaid, addressed as follows:

-40-

 

If to the Company:

Amicus Therapeutics, Inc.

6 Cedar Brook Drive

Cranbury, New Jersey 08512

Fax: (609) 662-2001

Attention: General Counsel

Copy to:

Bingham McCutchen

One Federal Street

Boston, Massachusetts 02110

Fax: (617) 428-6340

Attention: Meerie M. Joung, Esq.

If to the Trustee:

                                        

                                        

                                        

     The Company or the Trustee by written notice to the other may designate additional or
different addresses for subsequent notices or communications. Any notice or communication to the
Company or the Trustee shall be deemed to have been given or made as of the date so delivered if
personally delivered; when receipt is confirmed by telephone or electronic transmission report, if
sent by facsimile; and three Business Days after mailing if sent by registered or certified mail,
postage prepaid (except that a notice of change of address shall not be deemed to have been given
until actually received by the addressee).

     Any notice or communication mailed to a Securityholder shall be mailed to such Securityholder
by first-class mail, postage prepaid, at such Securityholder’s address shown on the register kept
by the Registrar.

     Failure to mail, or any defect in, a notice or communication to a Securityholder shall not
affect its sufficiency with respect to other Securityholders. If a notice or communication to a
Securityholder is mailed in the manner provided above, it shall be deemed duly given, three
Business Days after such mailing, whether or not the addressee receives it.

     In case by reason of the suspension of regular mail service, or by reason of any other cause,
it shall be impossible to mail any notice as required by this Indenture, then such method of
notification as shall be made with the approval of the Trustee shall constitute a sufficient
mailing of such notice.

     In the case of Global Securities, notices or communications to be given to Securityholders
shall be given to the Depository, in accordance with its applicable policies as in effect from time
to time.

-41-

 

     In addition to the manner provided for in the foregoing provisions, notices or communications
to Securityholders shall be given by the Company by release made to Reuters Economic Services and
Bloomberg Business News.

     10.3. COMMUNICATIONS BY HOLDERS WITH OTHER HOLDERS.

     Securityholders of any Series may communicate pursuant to TIA Section 312(b) with other
Securityholders of that Series or any other Series with respect to their rights under this
Indenture or the Securities of that Series or any other Series. The Company, the Trustee, the
Registrar and any other Person shall have the protection of TIA Section 312(c).

     10.4. CERTIFICATE AND OPINION AS TO CONDITIONS PRECEDENT.

     Upon any request or application by the Company to the Trustee to take any action under this
Indenture, the Company shall furnish to the Trustee:

     (1) an Officers’ Certificate (which shall include the statements set forth in Section
10.5 below) stating that, in the opinion of the signers, all conditions precedent, if any,
provided for in this Indenture relating to the proposed action have been complied with; and

     (2) an Opinion of Counsel (which shall include the statements set forth in Section 10.5
below) stating that, in the opinion of such counsel, all such conditions precedent have been
complied with.

     10.5. STATEMENT REQUIRED IN CERTIFICATE AND OPINION.

     Each certificate and opinion with respect to compliance with a condition or covenant provided
for in this Indenture (other than pursuant to Section 4.4) shall include:

     (1) a statement that the Person making such certificate or opinion has read such
covenant or condition;

     (2) a brief statement as to the nature and scope of the examination or investigation
upon which the statements or opinions contained in such certificate or opinion are based;

     (3) a statement that, in the opinion of such Person, it or he has made such examination
or investigation as is necessary to enable it or him to express an informed opinion as to
whether or not such covenant or condition has been complied with; and

     (4) a statement as to whether or not, in the opinion of such Person, such covenant or
condition has been complied with.

     10.6. RULES BY TRUSTEE AND AGENTS.

     The Trustee may make reasonable rules for action by or at meetings of Securityholders. The
Registrar and Paying Agent may make reasonable rules for their functions.

-42-

 

     10.7. BUSINESS DAYS; LEGAL HOLIDAYS; PLACE OF PAYMENT.

     A “Business Day” is a day that is not a Legal Holiday. A “Legal Holiday” is a Saturday, a
Sunday, a federally-recognized holiday or a day on which banking institutions are not authorized or
required by law, regulation or executive order to be open in the State of New York.

     If a payment date is a Legal Holiday at a Place of Payment, payment may be made at that place
on the next succeeding day that is not a Legal Holiday, and no interest shall accrue for the
intervening period. “Place of Payment” means the place or places where the principal of, and
interest and premium, if any, on, the Securities of a Series are payable as specified as
contemplated by Section 2.2. If the regular record date is a Legal Holiday, the record date shall
not be affected.

     10.8. GOVERNING LAW.

     THIS INDENTURE AND THE SECURITIES SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE
LAWS OF THE STATE OF NEW YORK, AS APPLIED TO CONTRACTS MADE AND PERFORMED WITHIN THE STATE OF NEW
YORK WITHOUT REGARD TO PRINCIPLES OF CONFLICTS OF LAW.

     10.9. NO ADVERSE INTERPRETATION OF OTHER AGREEMENTS.

     This Indenture may not be used to interpret another indenture, loan, security or debt
agreement of the Company or any Subsidiary thereof. No such indenture, loan, security or debt
agreement may be used to interpret this Indenture.

     A director, officer, employee, stockholder or incorporator, as such, of the Company shall not
have any liability for any obligations of the Company under the Securities or the Indenture. Each
Securityholder by accepting a Security waives and releases all such liability. Such waiver and
release are part of the consideration for the issuance of the Securities.

     10.10. SUCCESSORS.

     All covenants and agreements of the Company in this Indenture and the Securities shall bind
the Company’s successors and assigns, whether so expressed or not. All agreements of the Trustee,
any additional trustee and any Paying Agents in this Indenture shall bind their respective
successors and assigns.

     10.11. MULTIPLE COUNTERPARTS.

     The parties may sign multiple counterparts of this Indenture. Each signed counterpart shall be
deemed an original, but all of them together represent one and the same agreement.

-43-

 

     10.12. TABLE OF CONTENTS, HEADINGS, ETC.

     The table of contents, cross-reference sheet and headings of the Articles and Sections of this
Indenture have been inserted for convenience of reference only, are not to be considered a part
hereof, and shall in no way modify or restrict any of the terms or provisions hereof.

     10.13. SEVERABILITY.

     Each provision of this Indenture shall be considered separable, and if for any reason any
provision which is not essential to the effectuation of the basic purpose of this Indenture or the
Securities shall be invalid, illegal or unenforceable, the validity, legality and enforceability of
the remaining provisions shall not in any way be affected or impaired thereby, and a Holder shall
have no claim therefor against any party hereto.

     10.14. SECURITIES IN A FOREIGN CURRENCY OR IN EUROS.

     Unless otherwise specified in a Board Resolution, a supplemental indenture hereto or an
Officers’ Certificate delivered pursuant to Section 2.2 with respect to a particular Series of
Securities, whenever for purposes of this Indenture any action may be taken by the Holders of a
specified percentage in aggregate principal amount of Securities of all Series or all Series
affected by a particular action at the time outstanding and, at such time, there are outstanding
Securities of any Series which are denominated in a coin or currency other than Dollars (including
Euros), then the principal amount of Securities of such Series which shall be deemed to be
outstanding for the purpose of taking such action shall be that amount of Dollars that could be
obtained for such amount at the Market Exchange Rate at such time. For purposes of this Section
10.15, “Market Exchange Rate” shall mean the noon Dollar buying rate in New York City for cable
transfers of that currency as published by the Federal Reserve Bank of New York; PROVIDED, HOWEVER,
in the case of Euros, Market Exchange Rate shall mean the rate of exchange determined by the
Commission of the European Union (or any successor thereto) as published in the Official Journal of
the European Union (such publication or any successor publication, the “Journal”). If such Market
Exchange Rate is not available for any reason with respect to such currency, the Trustee shall use,
in its sole discretion and without liability on its part, such quotation of the Federal Reserve
Bank of New York or, in the case of Euros, the rate of exchange as published in the Journal, as of
the most recent available date, or quotations or, in the case of Euros, rates of exchange from one
or more major banks in New York City or in the country of issue of the currency in question or, in
the case of Euros, in Luxembourg or such other quotations or, in the case of Euros, rates of
exchange as the Trustee, upon consultation with the Company, shall deem appropriate. The provisions
of this paragraph shall apply in determining the equivalent principal amount in respect of
Securities of a Series denominated in currency other than Dollars in connection with any action
taken by Holders of Securities pursuant to the terms of this Indenture.

     All decisions and determinations of the Trustee regarding the Market Exchange Rate or any
alternative determination provided for in the preceding paragraph shall be in the Trustee’s sole
discretion, and shall, in the absence of manifest error, be conclusive to the extent permitted by
law for all purposes and irrevocably binding upon the Company and all Holders.

-44-

 

     10.15. JUDGMENT CURRENCY.

     The Company agrees, to the fullest extent that it may effectively do so under applicable law,
that (a) if for the purpose of obtaining judgment in any court it is necessary to convert the sum
due in respect of the principal of, or interest or premium, if any, or other amount on, the
Securities of any Series (the “Required Currency”) into a currency in which a judgment will be
rendered (the “Judgment Currency”), the rate of exchange used shall be the rate at which, in
accordance with normal banking procedures, the Trustee could purchase in The City of New York the
Required Currency with the Judgment Currency on the day on which final unappealable judgment is
entered, unless such day is not a Business Day, in which instance, the rate of exchange used shall
be the rate at which, in accordance with normal banking procedures, the Trustee could purchase in
The City of New York the Required Currency with the Judgment Currency on the Business Day preceding
the day on which final unappealable judgment is entered and (b) its obligations under this
Indenture to make payments in the Required Currency (i) shall not be discharged or satisfied by any
tender or any recovery pursuant to any judgment (whether or not entered in accordance with
subsection (a)) in any currency other than the Required Currency, except to the extent that such
tender or recovery shall result in the actual receipt, by the payee, of the full amount of the
Required Currency expressed to be payable in respect of such payments, (ii) shall be enforceable as
an alternative or additional cause of action for the purpose of recovering in the Required Currency
the amount, if any, by which such actual receipt shall fall short of the full amount of the
Required Currency so expressed to be payable and (iii) shall not be affected by judgment being
obtained for any other sum due under this Indenture.

-45-

 

     IN WITNESS WHEREOF, the parties hereto have caused this Indenture to be duly executed,
and their respective corporate seals to be hereunto affixed and attested, all as of the day and
year first above written.

	 	 	 	 	 
	 	 	AMICUS THERAPEUTICS, INC.
	 
	 	 	 	 
	 

	 	By:	 	 
	 

	 	 	 	 
	 

	 	Name:	 	 
	 

	 	 	 	 
	 

	 	Title:	 	 
	 

	 	 	 	 
	 
	 	 	 	 
	 	 	[Name of Trustee]
	 
	 	 	 	 
	 

	 	By:	 	 
	 

	 	 	 	 
	 

	 	Name:	 	 
	 

	 	 	 	 
	 

	 	Title:	 	 
	 
	 	 	 	 
	 

	 	By:	 	 
	 

	 	 	 	 
	 

	 	Name:	 	 
	 

	 	 	 	 
	 

	 	Title:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00157-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00157-of-00352.parquet"}]]